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Abstract (English)
The definition of the study population for a clinical
trial via the criteria for trial eligibility has
implications for the validity of the study and its
applicability to clinical practice. Though issues of equity
regarding the selection of subjects for research have long
been a concern of ethicists, issues regarding the impact of
subject selection on a trial's generalizability have only
recently attracted ethical scrutiny. After a review of the
history of the ethics of subject selection, l focus on three
empirical questions regarding the generalizability of
clinical trials. (1) What proportion of diseased populations
are studied in clinical trials? (2) How are subjects
selected for clinical trial participation (and what are the
main barriers to participation)? (3) Are clinical trial
participants comparable to non-participants? Finally, the
role of the Institutional Review Board -- Research Ethics
Board in Canada -- in assessing the generalizability of
clinical research is discussed .
••
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Abstract (French)
Définir la population étudiée dans le cadre d'un essai
clinique par le truchement des critères d'admissibilité à
l'essai revêt plusieurs conséquences sur la validité de
l'étude et ses possibilités d'application clinique. Le
problème de l'équité dans le choix des sujets aptes à la
recherche préoccupe depuis longtemps les éthiciens mais
l'intérêt qu'ils prêtent aux questions liées à l'impact de
la sélection des sujets sur le potentiel généralisable des
essais est récent. Après un passage en revue de l'évolution
de l'éthique de la sélection des sujets, je m'intéresse à
trois questions empiriques liées au potentiel généralisable
des essais cliniques : (1) Quelle est la proportion de
populations malades étudiées dans les essais cliniques? (2)
Comment les sujets sont-ils sélectionnés pour les essais
cliniques (et quels sont les principaux obstacles à leur
participation)? (3) Les participants aux essais cliniques
se comparent-ils aux non-participants? Enfin, j'examine en
détail le rôle des comités d'éthique de la recherche dans
l'évaluation du caractère généralisable de la recherche
clinique .
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Preface
In accordance with the Guidelines Concerning Thesis
Preparation l have taken the option, according to section
(7), of writing the experimental part of the thesis
(Chapters two and three) in the form of original papers
submitted for publication to learned journals. This
provision reads as follows:
The candidate has the option, subject to the
approval of the Department, of including as part
of the thesis the text, or duplicated text (see
below), of an original paper, or papers. In this
case the thesis must still conform to all other
requirements explained in the Guidelines
Concerning Thesis Preparation. Additional material
(procedural and design data as well as
descriptions of equipment) must be provided in
sufficient detail (e.g., in appendices) to allow a
clear and precise judgement to be made of the
importance and originality of the research
reported. The thesis should be more than a mere
collection of manuscripts published or to be
published. It must include a general abstract, a
full introduction and literature review and a
final overall conclusion. Connecting text which
provide logical bridges between different
manuscripts are usually desirable in the interests
of cohesion.
It is acceptable for theses to include as chapters
authentic copies of papers already published,
provided these are duplicated clearly on
regulation thesis stationary and bound as an
integral part of the thesis. Photographs or other
materials which do not duplicate well must be
included in their original form. In such
instances, connecting texts are mandatory and
supplementary explanatory material is almost
always necessary .
The inclusion of manuscripts co-authored by the
candidate and others is acceptable but the
4
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candidate is required to make an explicit
statement on who contributed to such work and to
what extent, and supervisors must attest to the
accuracy of such claims, e.g. before the Oral
Committee. Since the task of the Examiners is made
more difficult in these cases, it is in the
candidate's interest to make the responsibilities
of authors perfectly clear. Candidates following
this option must inform the Department before it
submits the thesis for review.
Thus, each chapter of this thesis bears its own
Abstract, Introduction, Methods, Results, Discussion and
References. AIso, as required by the Guidelines, there is a
common abstract, a general introduction (Chapter one) and a
general discussion (Chapter four) as weIl as claims to
originality and suggestions for further research.
The submitted manuscripts are as follows:
• Chapter 2. Weijer C. Eligibility criteria and other
barriers to enrollment in randomized controlled trials.
(Submitted for publication) .
• Chapter 3. Weijer C. Are randomized controlled trial
participants comparable to non-participants? -- A review of
the empirical literature. (Submitted for publication).
The candidate was responsible for aIl of the work in
both of these papers. Helpful advice and comments on earlier
versions of each of the papers was received from his
colleagues in the Clinical Trials Research Group, McGi11
University: Benjamin Freedman, Ph.D., Abraham Fuks, M.D.,
C.M., F.R.C.P. (C), Stanley Shapiro, Ph.D., Kathleen Cranley
••
Glass, D.C.L., Trudo Lemmens, LL.L. and Myriam Skrutkowska,
B.Sc.N ..
The candidate's work is supported by a fellowship from
the Medical Research Council of Canada. The candidate would
like to express his sincere gratitude to his colleagues in
the Clinical Trials Research Group for their encouragement
and support during the preparation of this thesis. He would
albO like to thank Anthony Belardo, B.A. and Elena Plotkin
who both provided editorial assistance with the thesis
manuscript. The candidate is particularly grateful to his
supervisors, Professors Benjamin Freedman and Abraham Fuks,
for their guidance, both intellectual and moral.
Wisdom has built her mansion,
and set up her seven pillars;
her beasts are slain, her wines are blended,
her table is prepared;
she has sent her maidens out to cry,
on the thoroughfares of the city,
"Let all who are heedless turn in here!N
She calls to him who is devoid of sense,
"Come, eat my bread,
drink wines that l have blended;
leave your foolish ways and live,
follow the ways of thoughtful sense. N
[Proverbs 9:1-6]
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Introduction
Issues involving the selection of subjects for clinical
research have occupied clinical trial designers and
ethicists for at least the last three decades. The selection
of subjects for clinical research is defined by criteria for
eligibility in the research protocol. When defining the
eligible population for a study, clinical trial designers
attempt to strike a balance between defining a homogeneous
study population (enhancing the validity of the study) and
including a diverse enough group of subjects such that the
results will be applicable to clinical practice (enhancing
the study's generalizability). Uncil relatively recently,
ethicists and research ethics committees -- Research Ethics
Boards (REBs) in Canada; Institutional Review Boards (IRBs)
in the United States -- had concerns regarding procedures
for the selection of subjects that, by and large, did not
overlap with those of trial designers.
Until recently, ethicists were largely concerned with
issues of justice in the selection of subjects: the
equitable distribution of the burdens and benefits of
research (discussed in detail below). The impact of the
criteria for research eligibility on the generalizability of
the research findings was not considered an ethical issue .
Recent regulatory changes, including the NIH Guidelines on
••
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the Inclusion of Women and Minorities as Subjects in
Clinica1 Research (1994), have given IRBs a mandate to
evaluate the eligibility criteria of research proposais with
regard to their impact on the generalizability of the
research findings.
'
These regulatory changes have been
paralleled by efforts to systematize approaches to the
ethical analysis of protocols which cali for the scrutiny of
eligibility criteria on the basis of their impact on
generalizability.2
l have therefore undertaken to study the impact of
eligibility criteria on the generalizability of randomized
controlled trials. Like any new intellectual tack, the
questions proposed and the results obtained must be viewed
in context. The context here is at least two fold: normative
and historical. The predominant normative context for
research ethics is set out by the Belmont Report.' The
historical context encompasses the shifting pattern of
ethical concerns relating to the selection of subjects for
research alluded to above. The purpose of this chapter is to
review these two subject areas, setting the stage for what
is to follow. The last brief section of this chapter will
list the study questions addressed in this thesis .
••
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The Belmont principles
In the Belmont Report, the members of the National
Commission for the Protection of Human Subjects of
Biomedical and Behavioral Research (hereafter, "National
Commission") set out three ethical principles that could
serve to describe the foundation of research ethics. 3 These
three princip1es -- respect for persons, beneficence, and
justice -- are "generally accepted in our cultural
tradition" and were chosen for their particular relevance to
the ethics of research. 3 Understanding that rules regarding
the ethical conduct of human experimentation would, at
times, conflict with each other, the National Commission
intended that the principles would "provide an analytical
framework that will guide the resolution of ethical problems
arising from research involving human subjects".3
Respect for persons. The princip1e of respect for
persons entails two ethical requirements. First, that tho
choices of an autonomous person -- "an individual capable of
deliberation about personal goals and of acting under the
direction of such deliberation" -- ought not to be
interfered with unless those choices are likely to harm
others. 3 Second, that persons who are not capable of
autonomous choice, inc1uding children, the menta1ly ill, and
(perhaps) persons who are incarcerated, are entit1ed to
••
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special protection.' In the context of research, the
principle of respect for persons is taken to require that
subjects of research must consent to participate. Consent
for research participation must be voluntary (i.e., not
coerced), informed (the subject must be informed of the
purpose of the research, the procedures involved,
alternatives, etc.), and comprehending (efforts must be
undertaken to ensure that the subject understands the
information relayed) .
Beneficence. The principle of beneficence in general
requires that efforts must be undertaken both to protect
persons from harm as weIl as to attempt to ensure their
wellbeing. The Belmont Report defines two complementary
rules that define beneficent actions: beneficent actions
"(1) do no harm and (2) maximize possible benefits and
minimize possible harms".' Thus, in the context of research,
the investigators and IRBs must assess the risks and
benefits that research presents to potential subjects to
ensure that a favourable risk-benefit ratio exists. The
principle also requires that potential research benefits to
society be considered. "Beneficence thus requires that we
protect against risk of harm to subjects and also that we be
concerned about the loss of substantial benefits that might
be gained from research".'
••
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Justice. The principle of justice demands that burdens
and benefits be di~tributed fairly. Conceptually, goods can
be justly distributed on the basis of a number of different
formulations such as "to each person an equal share" or, "to
each person according to individua1 need" and so on. (For a
detailed discussion of the different formulations of
distributive justice see Tom Beauchamp's chapter in the
appendix to the Belmont Report).4 In the context of research
ethics, justice demands that the burdens and benefits of
research be distributed equitably.
IRBs must scrutinize the procedures for the selection
of subjects for research to ensure justice on two levels:
individual and societal. On the level of the individual,
researchers "should not offer potentially beneficial
research only to sorne patients who are in their favor or
select only 'undesirab1e' persons for risky research".' On a
societal level, justice requires that classes of persons who
are already burdened in sorne way ought not be further
burdened by research unless it is necessary to do so.
Thus, it can be considered a matter of social
justice that there is an order of preference in
the selection of subjects (e.g., adults before
children) and that sorne classes of potential
subjects (e.g., the institutionalized mentally
infirm or prisoners) may be involved as research
subjects, if at aIl, only on certain conditions.'
••
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Evo1ving ethica1 concerns in the selection of subjects for
c1inica1 trials.
Wittgenstein, in his famous critique of logical
positivism, noted that the influence of an idea can be such
that it alters the way that we see the world. "It is like a
pair of glasses on our nose through which we see whatever we
look at", he said. "It never occurs to us to take them
off".s This view of the power of an idea suggests that the
interpretation of an event, and what response this event
calls for, can depend upon the view one has of the world
if you will, upon the pair of glasses through which you are
viewing the event. A person who is naive about medical facts
may, for exarnple, interpret chest pain upon exertion as be a
sign that he is "over doing it"; were he more medically
knowledgeable, the sarne symptom might be interpreted as a
possible indicator of coronary artery disease. The naive
interpretation calls for rest; the informed interpretation
calls for medical attention as weIl.
Like the changes in eye wear prescription that many
people undergo as they get older, our understanding of the
ethics of human experimentation has gone through a number of
evolutionary changes. This phenomenon is illustrated by the
shifting ethical concerns regarding the selection of
subjects for clinical research. Sequentially, each of these
••
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views has he1d a given ethica1 prob1em to be central to the
ethics of subject selection; in turn, each understanding of
the primary ethical prob1em entailed an approach to the
review of human subject research. l believe that the history
of the ethics of subject selection in human experimentation
can productively be divided into three periods.
It is not the case, though, that earlier concerns have
fallen by the wayside. Each of the sequentially voiced
ethical concerns continues to be relevant to the ethical
analysis of research. Indeed, over the last decades the
scope of ethical analysis regarding the selection of
research subjects has broadened, each prescription change
allowing us to see the world more clearly.
The 1970s: equitable distribution of burden
"Every family", observed the character Michael Corleone
in the Godfather saga, "has skeletons in its closet". Were
this proverb to be applied to human experimentation, it
would have to be admitted that research abides in a house
with many closets -- big, walk-in closets. The early history
of research ethics was shaped by a number of prominent
research scandaIs. Indeed, research ethics has been
described -- and l think accurately -- as having been "bom
in scandaI and reared in protectionism".6 The Nuremberg
••
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Code, often cited as the birth document of research ethics,
was a response to the horrifie experimentation undertaken by
the Nazis on Jews, gypsies, Russians and other politica1
prisoners during the Second World War. 7 Despite the
existence of the Nuremberg Code and the later developed
Declaration of Helsinki, the conduct of human
experimentation in the United States remained relatively
free of external regulation until the mid-1960s.
The perceived need for greater regulation of research
in the United States was sparked by the revelation of an
unsavoury experiment conducted in Brooklyn, New York. In
1963, three physicians at the Jewish Chronic Disease
Hospital injected 22 chronically-ill patients with live
cancer cells. 8 The purpose of the experiment was to
deterrnine if the lack of immune response against cancer
cells observed in cancer patients was due to the fact that
they had cancer or that they were chronically ill. Although
the investigators had reason to believe that the patients in
the study would "reject" the cancer cells, they could not be
sure. Problematically, the research subjects were neither
inforrned of the purpose of the experiment nor of the fact
that the injections contained cancerous cells. In the wake
of the public uproar resulting from the experiment, the
Public Health Service asked the National Advisory Health
••
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Council to "explore the advisability of establishing
guidelines for the conduct of human experimentation in its
extramural project-grants program".9 Acting on the
recommendations of the Council, Surgeon General Stewart
issued a directive in 1966 indicating that the Public Health
Service would not fund research unless it had been reviewed
by an independent committee of peers. 9
FormaI regulations for the conduct of human
experimentation in the United States were not instituted
until the revelation of yet another scandaI, the Tuskegee
Syphilis Study. In 1972, it came to light that the Public
Health Service had sponsored a study of 40 years duration in
which 400 African-American men with syphilis were left
untreated. 10 The study began in 1932, a time when the
treatment for syphilis was both toxic and not very
effective, and sought to determine whether the natural
course of syphilis was, as was then thought, more benign in
Afro-Americans. When penicillin -- a highly effective and
non-toxic treatment for syphilis -- became available in the
late 1940s, it was not offered to the study participants.
Furthermore, study participants were actively deceived as to
the nature of sorne study interventions. Spinal taps done
purely for research purposes, for example, were described to
participants as "treatments". As a result of the ensuing
••
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scandal, Merlin Duval, Assistant Se~retary of the Department
of Health, Education and Welfare (DHEW) struck an Ad Hoc
Advisory Panel to examine the Tuskegee Study and to examine
the need for federal regulations to govern research.· As a
result, in part, of the Panel's deliberations, the first
Policy for the Protection of Research Subjects was issued by
the DHEW in 1974.
Against this background of scandal and deceit, it is
not surprising that the research ethics literature of the
1970s tended to characterize participation in clinical
research as a risky endeavour. For example, Hans Jonas, in
his classic essay, "Philosophical reflections on
experimenting with human subjects" (1970), refers to
participation in research as a "sacrifice" and to research
participants as "martyrs"." Beginning with the premise that
research participation is perilous, Jonas reasons that
physician-researchers themselves ought to be the first
subjects of human experimentation. If necessary, the
scientists ~ research subjects could be supplemented with
other members of society beginning with the most educated
and prosperous. Thus, Jonas' scheme for subject selection
affords the most "captive" members of society -- the
uneducated, the impoverished -- the greatest protection from
the potential harms of research. For Jonas, the only way to
••
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make the selection of subjects for research just is a schema
that protects the disadvantaged from harm:
[a]n inversion of the normal 'market' behaviour is
demanded here -- namely, to accept the lowest
quotation last (and excused only by the greatest
pressure of need); to pay the highest price
first."
The National Commission shared Jonas' concern regarding
the risks inherent in research participation. ConDequently,
they too were preoccupied with the issue as justice ~ the
equitable distribution of burdens in the selection of
research subjects. For example, recommendation 4B in the
National Commission's Report and Recommendations:
Institutional Review Boards (1978) states that the IRB must
ensure that the "selection of subjects is equitable".'2
A1though this recommendation in itself could refer to the
equitable distribution of either burden or benefit, the
commentary that follows renders their fixation on burden
perspicuous:
[Comment on recommendation 4Bl The proposed
involvement of hospitalized patients, or other
institutionalized persons, or disproportionate
numbers of racial or ethnic minorities or persons
of low socioeconomic status should be justified.'3
The National Commission was motivated by past abuses to
ensure that vulnerable subjects would be protected from
human experimentation. The connection between the research
scandaIs of the past and issue of justice in the selection
••
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of subjects is explicitly drawn in the Belmont Report
(1979). After a listing a bestiary of past abuses (including
sorne of the cases discussed above), the members of the
National Commission conclude that
[a]gainst this historical background, it can be
seen how conceptions of justice are relevant to
research involving human subjects. For example,
the selection of research subjects needs to be
scrutinized in order to determine whether sorne
classes (e.g., welfare patients, particularly
racial and ethnic minorities, or persons confined
to institutions) are being systematically selected
simply because of their easy availability, their
compromised position, or their manipulability,
rather than for reasons directly related to the
problem being studied. 3
The notion that classes of subjects need to be protected
from research is one that continues through to the most
recent regulations for the Protection of Human Subjects from
the Department of Health and Human Services (1991). Indeed,
the sum total of the regulations' comments regarding the
selection of subjects is as follows and seems to reflect
this preoccupation with the equitable distribution of
burden:
[§46.111(a)] In order to approve research covered
by this policy the IRB shall determine that aIl of
the following requirements are satisfied:
(3)Selection of subjects is equitable. In making
this assessment the IRB should take into account
the purposes of the research and the setting in
which the research will be conducted and should be
particularly cognizant of the special problems of
research involving vulnerable populations, such as
children, prisoners, pregnant women, mentally
••
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disabled persons, or economically or educationally
disadvantaged persons
(7) (b)When sorne or all of the subjects are likely
to be vulnerable to coercion or undue influence,
such as children, prisoners, pregnant women,
mentally disabled persons, or economically or
educationally disadvantaged persons, additional
safeguards have been included in the study to
protect the rights and welfare of these
subjects. 14
It should be noted that category of so-called
"vulnerable populations" is not only composed of those (e.g.
pregnant women) who may be unduly susceptible to harm from
research participation. Indeed, the majority of groups
listed in this category are those who may be unable to give
free and informed consent to research participation. Thus,
the concept of equity in the distribution of the burden of
research participation remained closely tied to concerned
related to the principle of respect for persons. Levine in
his book Ethics and Regulation of Clinical Research explains
the connection as follows:
[B)ecause we define as vulnerable those persons
who are relatively or absolutely incapable of
protecting their own interests through
negotiations for informed consent, in the
practical area of IRB review, there is often an
interplay between considerations of informed
consent and selection of subjects. To the extent
that the subject population can be made less
vulnerable in the sense of becoming more capable
of protecting their own interests, fewer
procedures are needed to assure the validity of
their consent. l5
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Although little empirical information regarding the
activities of Institutional Review Boards is available, it
seems that their actions in the 1970s were in keeping with
the protectionist ter.or of the times. The most extensive
survey of IRBs is contained within the National Commission's
Appendix to Report and Recommendations: Institutional Review
Boards.'· Although IRBs tended to be much more preoccupied
with issues of consent, approximately 4% of research
protocols reviewed by IRBs had changes made to procedures
for the selection of subjects. In f~lly 75% of these cases
the changes required limited the scope of the study's
sample; no case of an IRE requiring that subjects be added
to a study is reported. The end result of the protectionist
stance was that riskier research tended, by and large, to be
done on middle aged males who reported high or middle annual
incomes .'7
The 1980s: equitable distribution of benefit
The turn of decade heralded a dramatic change in the
public's perception of clinical research. In the span of a
few short years, research, once perceived as risk laden,
came to be seen as a source of potential benefit. Levine:
what was once seen as threatening -- a burden from
which people would wish to be protected -- is now
seen as a benefit. People are clamouring for
access to clinical trials and to experimental
••
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drugs. people are demanding that they, and others
who are like them, are owed such as a matter of
justice.'"
While the emergence of HIV/AIDS and AIDS activism certainly
had much to do with the change in public attitude, a number
of events prior to the advent of HIV/AIDS set the scene for
change.
The thalidomide disaster in the early 1960s had a
substantial impact both upon public perceptions of the
potential hazards of pharmaceutical agents and on the
regulation of new drug approval. In 1962 United States
Congress passed the Kefauver-Harris amendments to the drug
approval laws which required for the first time that the
Food and Drug Administration (FDA) ensure that drugs were
not only safe but also effective before they could be
licensed. By the late 1970s, though, objections were being
voiced by industry to the inordinate time delays involved in
the drug licensure process. '9 Eventually, in 1983 FDA
modified sorne of its procedures to attempt to speed the drug
approval process. 19
Coincident with these events, a series of studies was
published (1976 to 1982) which attempted to quantify the
risk to subj ects conferred by research participation. 20.21.22.23
Overall, the studies indicated that participation in
research was a relatively safe activity. Non-therapeutic
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trials, including phase l studies to test the safety of new
drugs in humans, seem to pose the least risk to
participants." Therapeutic studies, including phase II and
phase III clinical trials, tended to pose more risk to
subjects than non-therapeutic studies.'3 Even so, the
majority of the serious adverse events seemed to be related
to toxic therapy, such as chemotherapy for persons with
cancer, which posed risks to subjects that were similar (at
least in kind) to those present in clinical practice.'o
Clearly, though, HIV/AIDS had the most substantial
impact on the public's perception of clinical research.
Although the disease was first recognized in 1981, no
antiviral therapy was tested for efficacy against the
disease until 1986. Thus, for five years, no proven
treatment existed for HIV/AIDS. The first randomized
controlled trial of zidovudine (AZT) was a phase II, placebo
controlled trial: 145 subjects received AZT, while 137
received placebo.'4 Most of the subjects were white,
homosexual men; a1l had either AIDS or ARC (AIDS-related
complex; a pre-AIDS syndrome); and, intravenous drug abusers
were explicitly excluded from study participation. Although
accrual to the study was completed on June 30, 1986, the
study was stopped only three months later. By September, the
advantage conferred to subjects treated with AZT was
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obvious: 16 subjects had died on the placebo arm compared to
only one treated with AZT.
As the results of the AZT trial became widely known,
persons with HIV called for access to therapy with AZT (or
other promising treatments) but, were unable, in many cases,
to obtain it outside of clinical trials. Persons with
HIV/AIDS responded vocally and called for access to
experimental treatments. Groups such as ACT-UP (nAIDS
Coalition to Unleash Power") staged protests that were
effective in raising the public's awareness of the issue.
The des ire of patients to gain access to the potentially
life-saving treatments in trials was great: in sorne cases,
patients (occasionally with the aid of their physicians)
falsified medical data to satisfy the criteria for trial
eligibili ty. 19
Participation in research had, at times in the past,
been seen as a benefit. In the early debate on the
permissibility of including prisoners in clinical research,
sorne prisoners voiced the opinion that research
participation was a benefit -- monetary rewards for
participation exceeded other prison jobs and, perhaps more
importantly, it represented an opportunity to be altruistic.
The shift that occurred with HIV/AIDS, though, was that sorne
groups in society began to see trial participation as
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essential to their own medical care and, ultimately, to
their own chances for survival.
The events of the 1980s shaped the nature of the
discourse of research ethics at the time. Carried along by
the events of the day, ethicists too came to see access to
trials as the prime issue in the selection of subjects. The
issue remained one of justice but the emphasis had shifted
from equitable distribution of burden to the equitable
distribution of benefit. As a result, ethicists began to
question the exclusion of groups of patients from clinical
trials. For example, writing in 1986, Macklin and Friedland
write:
As well as the problem of fair distribution of the
burdens of research, the issue of justice in AID5
research also seems to include the opposite
problem: Who will receive the benefits of ear1y
testing of promising new drugs? The prob1em is
already apparent in the phase II study of AZT,
which was performed almost entirely on homosexual
male patients, excluding intravenous drug abusers.
Although drug abusers were excluded according to a
'medical' rationale -- this group tends to be
'unreliable' and 'noncompliant', and hence is not
a good study population -- the resulting
distribution of benefits was nonetheless unjust.'4
When participation in research came to be seen as a
benefit, the exclusion of potentially vulnerable groups from
research fostered by the protectionism of the 1970s came to
be seen itself as an injustice. For examp1e, Carol Levine,
writing in 1988, asks:
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How can groups of prospective subjects
traditionally excluded from clinical trials
because of their physical or social vulnerability
(women of childbearing age, infants prisoners,
intravenous drug users, prostitutes) be given
access to clinical trials that may, perhaps, prove
of benefit to them?24
Thus, towards the latter part of the decade and into the
early 1990s, researchers and IRBs alike were advised that
the exclusion of groups of affected individuals would have
to be carefully justified. For example, consensus statement
7 from Carol Levine et al.'s "Building a new consensus:
ethical principles and policies for clinical research on
HIV/AIDS" stated that:
Criteria for inclusion in phase II and III
clinical trials should be based on a presumption
that all groups affected by the research are
eligible, regardless of gender, social or economic
statuR, use of illicit drugs, or stage of illness
unless the study is particularly designed to look
at a particular stage of illness.
'
•
Although such requirements have yet to make their way into
the Department of Health and Human Services Regulations
(cited supra), the Institutional Review Board Guidebook
published by the Office for Protection from Research Risk
does require IRBs to consider the following points when
reviewing research:
• "To the extent that benefits to the subject are
anticipated, are they fairly distributed? Do other groups of
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potential subjects have a greater need to receive any of the
anticipated benefit?";
• "Has the selection process overprotected potential
subjects who are considered vulnerable (e.g., children,
cognitively impaired, economically or educationally
disadvantage persons, patients of researchers, seriously ill
persons) so that they are denied opportunities to
participate in research?".25
But, do IRBs change or eliminate eligibility criteria
on the basis of equitable distribution of benefits? To the
best of my knowledge, no recent, comprehensive empirical
study of the activity of IRBs has addressed this issue.
Freedman recently reviewed the actions of a single committee
over a two year period (February 1990 to January 1992) .26 Of
191 protocols approved by the committee, twenty-five
protocols had at least one eligibility criterion changed by
the committee. According to Freedman, in five cases (20%) an
eligibility criterion requiring an HIV test was dropped. My
own experience on that same committee (1994) and another IRB
(1993 to present) -- encompassing the review of perhaps 300
protocols -- leads me to believe that it is not rare for
committees to question eligibility criteria that exclude
certain groups -- particularly women of reproductive age,
the elderly, persons with a history of drug or alcohol
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abuse, and otherwise healthy persons with HIV -- who might
benefit from research participation. A systematic study of
the actions of IRBs in this regard is required to answer
this question definitively.
The 1990s: applicability of the results of research
In the 1990s, a new issue has been added to the ethical
debate regarding the inclusion of groups hitherto excluded
from research, namely, that if the results of research are
to be widely applicable, i.e., maximally beneficial to
society, then subjects included in research studies must be
representative of the population of persons affected.
Constructed as such, the issue is beneficence -- social
benefit -- rather than justice.
Concern in the ethics literature regarding the
applicability of narrowly focussed studies to the population
at large can be traced to the early HIV/AIDS literature. For
example, Macklin et al (1986) points to
a lack of information on the efficacy of AZT on a
wider group of AIDS patients, stemming from the
fact that the demography of patients studied did
not replicate the entire population of individuals
with AIDS. For example, few women and no children
or intravenous drug abusers were included in the
study.24
A relatively muted voice in the early ethical debates
regarding subject selection, a call for broader inclusion of
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subjects based on concerns regarding the applicability of
study results receive equal attention with justice-based
arguments in Carol Levine et al.'s "Building a new
consensus: ethical principles and policies for clinical
research on HIV/AIDS" (1991). For example, in arguing for a
presumption of inclusiveness in the selection of subjects
for trials the authors argue that
[i]t is essential that data be developed to serve
the we1l-being of all groups affected by the
research [beneficence] ... In addition, it is
necessary to assure equitable access to clinical
trials for all affected groups within communities
[justice] .19
In the same year (indeed in the same issue of IRB) ,
Carol Levine drew the connection between the existence of
possible biological differences in the way HIV/AIDS affects
women and inability to extrapolate treatment data derived
from studies of men to the treatment in c1inical practice of
women with HIV/AIDS. 27 Given these biological differences,
she argues, studies would need to enroll sufficient numbers
of women to address separately questions such as the
efficacy of a drug and the drug's optimal dose (for women).
When these issues are not adequately addressed in clinical
studies Levine claims that women suffer because
practitioners have insufficient information to treat them
properly. Not only must barriers to enrollment of women in
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studies be removed, but women must be adequate1y represented
in studies. This, she observes, will require
[rlecruitment efforts ... [thatl take account of the
multiple ro1es HIV-infected women play as fami1y
care givers and emp10yees (often in marginal jobs
with few opportunities for f1exibi1ity). Meeting
their own hea1th care needs may not be their
highest priority; enro11ing in research, an a1ien
concept to many, may seem 1ess important. 28
Starting in 1992 and continuing to the present, the
issue of the app1icabi1ity of research resu1ts dramatica11y
increased in scope. In an inf1uentia1 article in the
Hastings Center Report in 1992, Rebecca Dresser argued that
the exclusion of women from trials pertained to more than
HIV/AIDS research: "the fai1ure to inc1ude women in research
populations", she observed, ois ubiquitouS",>8 Indeed,
according to Dresser, not on1y women, but a1so racial and
ethnie minorities are 1arge1y underrepresented in research
designed to estab1ish the efficacy of new medica1
treatments. Pointing to the bio1ogica1 differences that may
exist between genders and amongst racial and ethnie groups,
she conc1udes that "[sluch differences make it inappropriate
to genera1ize findings based on one gender or racial group
to a11 human beings".2' Thus, optimal c1inica1 trials will
inc1ude representative numbers of both women and
racial/ethnie minorities. The main ethica1 issue at stake
is, for Dresser, beneficence:
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The current disparity between the health
information we have about white males and the
information we have about women and people of
color contravenes basic ethical principles
governing human experimentation. Most clearly
violated is the principle of beneficence, which
holds that biomedical research should be designed
to maximize benefit and minimize harm. 29
Following Carol Levine, Dresser notes that special
recruitment efforts may be needed to redress the
underrepresentation of these groups in clinical research.
If scientists conducting [for examplel heart
disease research are afraid that physicians will
not refer enough fema1e patients, then extra
recruiting measures should be taken to ensure that
they do. Research costs may go up, but the
benefits of including women subjects [and
minori ties l are worth the expense. 29
In 1993, p01iticians entered the fray. In that year,
the U.S. Food and Drug Administration released its
"Guidelines for the study and evaluation of gender
differences in the clinical evaluation of drugs". The new
guide1ines withdrew the Agency's long-standing prohibition
on the participation of women of childbearing potential in
early clinical trials. Ethical arguments regarding the
applicability of research results clearly influenced the new
FDA policy. Although the new Guidelines did not require the
inclusion of women in studies in aIl cases, the Guidelines
state that
The patients included in clinical studies should,
in general, reflect the population that will
receive the drug when it is marketed. For most
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drugs, therefore, representatives of both genders
should be included in clinical trials in numbers
adequate to allow detection of clinically
significant gender-related differences in drug
response ... Such analyses of subsets with
particular characteristics can be expected to
detect only relatively large gender-related
differences, but in general, small differences are
not likely to be clinically important."
The change in FDA policy reflects a shift from policy
grounded in non-maleficence -- avoiding harm -- to a policy
concerned with beneficence, that is, ensuring the wide-
spread applicability of research results. The absence of
reference in the Guidelines to arguments based on the
equitable distribution of benefit is noteworthy.
Perhaps even more significant than the changes to the
FDA regulatory policy was the signing into law in June 1993
of the "Clinical Research Equity Regarding Women and
Minorities· provision of the NIH Revitalization Act. The law
required the Director of NIH to construct guidelines to
ensure that both women and minorities are included as
subjects of NIH funded research. The new NIH Guidelines,
published in 1994, require that
[T]he NIH must:
• Ensure that women and members of minorities and
their subpopulations are included in all human
subject research .
• For phase III clinical trials, ensure that
women and minorities and their subpopulations must
be included such that valid analyses of
differences in intervention effect can be
accomplishedi
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• Not allow cost as an acceptable reason for
excluding these groups; and,
• Initiate programs and support for outreach
efforts to recruit these groups into clinical
studies. 30
As with the FDA Guidelines, the new NIH Guidelines were
justified with arguments based on the applicability of
research results:
Since a primary aim of research is to provide
scientific evidence leading to a change in health
policy or a standard of care, it is imperative to
determine whether the intervention or therapy
being studied affects women or men or members of
minority groups and their subpopulations
differently. To this end, the guidelines published
here are intended to ensure that all future NIH-
supported biomedical and behavioural research
involving human subjects will be carried out in a
manner sufficient to elicit information about
individuals of both genders and the diverse racial
and ethnic groups and, in the case of clinical
trials, to examine differential effects on such
groups.31
Clearly, these changes to the NIH and FDA regulations
will have implications for the design of trials and their
review by Institutional Review Boards. As required by
justice-based concerns, an IRB must carefully scrutinize the
justifications for eligibility criteria that deny access to
population groups to clinical trials. Beneficence, and in
particular the issue of the applicability of the results of
trials, implies additional duties. (These are outlined in a
letter to IRBs by Gary Ellis, Director of the Office for
Protection from Research Risk, April 25, 1994). For NIH
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funded research, IRBs have to ensure that adequate
representation of certain groups wi.thin the trial is likely.
This certainly entails scrutinizing proposed eligibility
criteria for studies. This also entails that the IRB:
(a)review procedures for subject recruitment, particularly
the recruitment of subjects from hard-to-access groups
including intravenous drug users and African-Americans;
(b)require the development and review of programs to attempt
to ensure the continued participation of subjects in the
study; (c)finally, IRBs may require, as a part of their
annual review process, that investigators provide them with
demographic information regarding accrual to ensure that
these procedures are effective. As these changes have just
taken effect in the 1995 fiscal year, no empirical data are
available to document the actual role that IRBs are playing
in this regard.
We have seen that a succession of issues have been
viewed by ethicists to be the prime issue in the selection
of subjects for clinical research. Each of these changes in
focus has been the result of a complex interaction among
current events (e.g. the revelation of scandal), political
factors (e.g. advisory panels, new regulations) and
ethicists themselves (e.g. Dresser's article undoubtedly
influenced the political debate). Overall, the most dramatic
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shift surrounding the selection of subjects for trials has
been the shift from "excluding" the vulnerable to a
presumption to include persons from all groups. This change
has paralleled a shift in the public's perception of
participation in trials from a risky activity to one that
possibly offers benefit.
In dividing the ethical concerns into three issues and
in assigning these issues to decades, we have, no doubt,
done sorne violence to the true complex interplay of these
issues. Indeed, all three of the issues -- equitable
distribution of burden, equitable distribution of benefit,
and the applicability of research results -- currently
occupy the thoughts and activities of ethicists and IRB
members. Each new area of ethical concern in the selection
of subjects added to the range of ethical inquiry; in turn,
the scope of the review of protocols by IRBs progressively
enlarged.
This narrative has described two general trends. First,
that concerns of research ethicists (and IRBs) regarding the
selection of subjects for research has shifted in emphasis
over the last three decades. Second, that the scope of
ethical inquiry regarding selection of subjects has
broadened over the same time; first including the protection
of subjects, then expanding access to clinical trials, and
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finally, encompassing the issue of the applicability of the
results of trials to clinical practice.
Study questions
Given these recent developments in the regulation and
ethics of clinical research, the impact of eligibility
criteria on the generalizability of randomized controlled
trials represents an important area of inquiry. Rather than
a strictly philosophical or historical approach to the
issue, l propose to undertake an approach that is partly
empirical. Thus, in the following two chapters l will
address the following questions:
• Is a large proportion of patients with a given disease
treated in clinical trials?
• Are subjects randomly selected from the patient
population for participation in clinical trials?
• Are clinical trial participants comparable to non-
participants?
Each of these questions bears on the generalizability
of the results of clinical trials. For each of the study
questions an affirmative answer is consistent with the
conclusion that the results of clinical trials are widely
generalizable .
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The final chapter of the thesis will review the
findings presented in chapters two and three and will place
those findings within the context that we have laid out
here. A final section will address the implications of this
research for the review of clinical research by ethics
boards -- REBs or IRBs .
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Abstract
Introduction. Despite the central role of the randomized
controlled trial in the genesis of medical knowledge, only a
small proportion of patients are treated in RCTs. This fact
may have implications for the time needed to complete trials
and for the generalizability of the results of trials to
clinical practice.
Methods. A review of empirical studies was undertaken in
order to quantify the relative contributions of eligibility
criteria, physician refusals and patient refusals to the
failure to enroll subjects in RCTs. Empirical studies
reporting on the enrollment of subjects to RCTs were
retrieved from the Medline (1966-1994) and Cancerlit (1983-
1994) databases. The number of subjects excluded due to
eligibility criteria, physician refusal, patient refusal or
other factors was recorded.
Resu1ts. Criteria for trial eligibi1ity proved to be the
largest barrier to trial enrollment. Overall, 53% of
subjects for whom a trial was available for their type and
stage of disease were ineligible for trial participation.
Physician refusal and patient refusal each accounted for
exclusion of 7% of the potential subjects (1% were excluded
for other reasons) .
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Discussion and Conclusion. Since many eligibility criteria,
particularly in North American RCTs, may be unnecessary,
trial designers ought to hold broad-based, pragmatic trials
as an ideal. Furthermore, individual eligibility criteria,
when included in a clinical trial protocol, ought to be
justified to highlight their necessity. The relaxation of
criteria for clinical trial enrollment, when combined with
other approaches, ought to increase the proportion of
patients treated in RCTs .
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Introduction
The randomized contro11ed trial (RCT) is the gold
standard in the eva1uation of the safety and efficacy of
nove1 medica1 interventions. On1y a sma11 proportion of
cancer patients, however, are enro11ed in RCTs. Tate et al.
reviewed enro11ment of cancer patients in RCTs in the United
Kingdom and found that on1y 3.7% of patients were treated in
tria1s. 1 Friedman et al. reviewed enro11ment in National
Cancer Institute (NCI) funded trials in the United States
and found that on1y 1.6% of car.cer patients were treated in
phase II and III c1inica1 tria1s. 2 Since cancer is one of
the diseases most active1y studied by c1inica1 research, it
is 1ike1y that on1y a sma11 proportion of other patient
populations are enro11ed in randomized contro11ed trials.
The enro11ment of a sma11 proportion of patients in
RCTs is not, in itse1f, a prob1em. 50 long as RCTs can
enro11 subjects at a sufficient rate to answer efficient1y
c1inica1 questions and so long as subjects enro11ed in RCTs
are reasonab1y representative of patients in c1inica1
practice, it matters 1itt1e what proportion of patients is
treated in trials. Unfortunate1y, both of these conditions
may be 1acking. The NCI has reported that many of its RCTs
have rates of enrol1ment that are considerab1y slower than
the p1anned rates.' This means that periods for subject
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enrollment for RCTs may last from 3 to 5 years or even
longer.' Enrolling a larger proportion of patients in RCTs
could solve this problem.
Regarding the second condition, Begg et al. have
pointed out that criteria for clinical trial eligibility are
frequently so restrictive as to call into question the wide-
spread applicability, or generalizability, of the results of
RCTs. 4 The enrollment of a larger proportion, or at least a
more representative proportion, of patients to RCTs is
required.
Why are so few subjects enrolled in randomized trials?
Protocol factors, physician factors and patient factors have
all been cited as contributing to the low proportion
enrolled. 4 • 5 • 6 In 1991, Gotay reviewed empirical studies that
examined the relative contribution of each of these factors
to exclusions from RCTs.' Gotay found that "fewer than half
of the availab1e patients were eligible for a particu1ar
clinical trial".' She also concluded that physician and
patient factors added substantial losses to trial
enrollment.'
Gotay's review, however, has serious flaws. We are not
told how the studies were retrieved for the review, nor are
all of the relevant studies incorporated therein. More
fundamentally, when labelling subjects as "ineligible",
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Gotay fails to separate two groups of subjects. The first
group is comprised of subjects for whom no RCT is available
for their type and stage of disease. The second, and more
important group, is comprised of subjects for whom a trial
is available but who fail to fulfil the criteria for
clinical trial eligibility. Since the results of a RCT
potentially apply to subjects in the second group but not to
those in the first, it is only the exclusion of subjects in
the second group that brings the generalizability of the
trial's results into question. A systematic review of the
empirical literature is thus required to assess and quantify
the relative contributions of protocol, physician and
patient factors to enrollment losses in RCTs.
Methods
Published reports of empirical studies were retrieved
through searches of the Medline and Cancerlit databases for
all available publication years (i.e. Medline: 1966 through
October, 1994; Cancerlit: 1983 through September, 1994). The
fol1owing keywords were used to define the searches:
"clinica1 trials" and "eligibility determination", "patient
participation" or "registries". The searches were
supplemented with articles cited in the bibliographies of
relevant papers. The names of the authors, publication year,
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study population and sample size were recorded from each
study. Subjects of trials noted in these studies were then
divided into one of the following mutually exclusive and
exhaustive categories:
(l)Subject enrolled in a RCT or,
Subject not enrolled in a RCT due tOi
(2) the absence of a protocol for his or her type
and stage of disease;
(3) failure to meet the criteria for trial
eligibility (but not due to 2);
(4) refusai of his or her physician to enroll them
(but not due to 2 or 3);
(S) subject refusai to consent to study
participation (but not due to 2, 3 or 4, unless
ineligibility is solely due to refusai to
consent); or,
(6) other (or unknown) reasons (i.e. not due to 2,
3, 4 or S).
In most cases, the actual number of subjects in each
category was reported in the study. In sorne cases, numbers
of subjects had to be reconstructed from reported
percentages. In a few cases, information on one or more
categories was not available. Studies were included in this
review if they reported at least the number of subjects
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excluded due to criteria for clinical trial eligibility.
Studies were divided into three groups: (1) studies
that assessed a population cohort for eligibility for two or
more randomized controlled trials (hereafter, group 1); (2)
studies that assessed a population cohort for eligibi1ity
for a single RCT (group 2); and, (3) studies reporting
patient logs from individual RCTs in which subjects with a
given type and stage of disease were assessed for
eligibility (group 3). To ensure that the mean proportions
summed to unity, only studies that reported information on
aIl categories were included in the calculation of
descriptive statistics.
proportions were ca1culated using the number of
subjects for whom a trial was available as the denominator.
This approach allowed for the possibility of combining
results across groups since group 3 studies only assessed
subjects for whom a trial was available. Furthermore, for
the reason outlined above, this denominator is the most
relevant to the assessment of the generalizability of trial
results. Both unweighted and weighted (for sample size) mean
proportions were calculated for each study group. It was
decided a priori that overall (across groups) estimates
would be calculated only if the results from each of the
groups were comparable.
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Results
The review of the literature retrieved twenty-two
studies from twenty articles that document the eligibility
of 148,561 subjects for randomized controlled trials. The
RCTs in question addressed the treatment of patients with
cancer, heart disease, affective disorders and stroke. Nine
studies (from eight articles) fell into group 1 (N=69,323)
and five studies fell into group 2 (N=26,070). It is likely
that the search strategy retrieved from the literature aIl
or most of the existing studies in these first two groups.
Eight studies (from seven articles) documenting the
eligibility of 53,168 subjects fell into group 3. As RCTs
are reporting results from patient logs with increasing
frequency, these eight studies very likely represent only a
small proportion of such studies in the literature.
Seventeen of the twenty-two studies reported information on
aIl of the categories and were thus included in the
calculation of descriptive statistics. In aIl, these
seventeen studies document the enrollment experience of
51,736 subjects for whom a clinical trial was available.
The data from the studies in group 1 are reported in
table 1. 8.'.10.11.12.13.14.15 A large percentage (37%) of the
subjects assessed for RCT enrollment had no trial available
to them. Of the subjects for whom a trial was available,
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only 36% were finally enrolled in a RCT. Failure to fulfil
criteria for clinical trial eligibility excluded the largest
proportion (45%) of subjects for whom a trial was available,
followed by physician refusaI (9%), patient refusaI (9%) and
other reasons (1%). Weighted means are reported and provide
similar resu1ts.
The data from the studies in group 2 are reported in
table 2.'6.'7.18.".20 Of the subjects assessed in these studies,
55% had the "wrong" stage of disease and thus had no trial
available to them. of those for whom a RCT was available,
29% were enrolled. 58% of subjects for whom a trial was
available were not enrolled due to ineligibility, 7% due to
physician refusaI, 4% due to patient refusaI and 2% for
other reasons. The weighted mean proportions revealed
similar results.
The data from the studies in group 3 are reported in
table 3.21.22.23.24.25.26.27 In total, 30% of the subjects were
enrolled in a RCT. 56% of the subjects for whom a trial was
available were excluded due to ineligibility, 4% were
excluded due to physician refusaI, 9% were excluded due to
patient refusaI and 1% were excluded for other reasons.
Weighted means were comparable to the unweighted means
reported .
Since the descriptive statistics were similar in aIl
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three groups, they were.combined into summary descriptive
statistics. These summary statistics are presented in figure
1. The unweighted means are as follows: of subjects for whom
a trial was available, 32% were enrolled in a randomized
controlled trial, 53% were ineligible for trial
participation, 7% were excluded due to physician refusal, 7%
refused to consent to participate, and 1% were excluded for
other reasons. Weighted means were similar to these reported
values (35%, 47%, 9%, 6%, and 3%, respectively).
Finally, substantial differences were noted between
studies based in North America and those based elsewhere.
(Of the seventeen studies with complete results, all were
conducted either within North America or elsewhere; that is,
none were conducted both within and outside of North
America: so the above categories do not overlap). In the
nine North American studies, only 19% (weighted mean) of
subjects for whom a trial was available were enrolled in a
ReT. 55% of those for whom a trial was available were
excluded due to ineligibility, 15% were excluded due te
physician refusal, 9% were excluded due to patients refusal,
and 2% were excluded for other reasons. In the eight studies
net based in North America, 58% (weighted mean) of subjects
for whom a trial was available were enrolled in a trial,
nearly three times the proportion enrolled in North American
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studies. 36% of subjects for whom a trial was available were
excluded due to ineligibility, 0% were excluded due to
physician refusaI, 3% due to patient refusaI, and 3% for
other reasons.
Discussion
The observant reader will have noted a discrepancy in
our figures. According to our literature review, 32% of
patients for whom a trial is available are enrolled in
clinical trials. But the actual proportion of cancer
patients enrolled in RCTs, as noted at the start of the
paper, is one-tenth of this figure. Why is this so? First,
many disease types and stages have no RCT available for
them. In our first group of studies, 37% of incident cases
had no trial available. Second, in other cases, classes of
patients may not themselves be "available" to be considered
for enrollment in a RCT. One class of patients who are
potentially "unavailable" are those treated outside of
tertiary-care centres. Efforts to extend RCTs to include
community hospitals have proven an effective way of
increasing trial enrollment. 28,29.30 Another class of
"unavailable" patients are those whose physician is unaware
of the existence of individual RCTs or may be reluctant to
enter patients (in general) in trials for a variety of
••
55
reasons. 5 In response to this, the NCI's Office for Cancer
Communications has initiated a program to heighten the
awareness of both physicians and patients of individual
clinical trials.' If enrollment in RCTs is to be maximized,
though, barriers to the enrollment of subjects who have a
trial available for them will need to be addressed.
This review demonstrates that criteria for clinical
trial eligibility are the largest barrier to RCT enrollment
for subjects who potentially have a trial available to them
(and who themselves are available for trial participation) .
Physician refusaIs and patient refusaIs each account for
less than one-seventh of the proportion of subjects excluded
~ eligibility criteria. But are any of the enrollment
losses due to eligibility criteria avoidable? Put another
way, are aIl of the eligibility criteria in clinical trials
necessary?
There are several indirect lines of evidence which
suggest that sorne eligibility criteria may be unnecessary.
Begg et al. reviewed eligibility criteria in nine concurrent
RCTs for the treatment of breast cancer.' They found that
the trials studied contained many eligibility criteria, sorne
of which were seemingly arbitrary. Substantial variation
among trials was noted in criteria that defined the maximum
time allowable since surgery, acceptable values for tests of
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organ function and concomitant disease exclusions. Begg et
al . ...:oncluded that "the variation [in criteria] observed
represents a lack of consensus on the need for specifie
restrictions. Moreover, the greater the variation across
studies, the more we must be skeptical about the value of a
particular restriction".'
Our own comparison of a twenty-year sample of breast
cancer trials from the National Surgical Adjuvant Breast
Project (NSABP) with a set of acute lymphocytic leukaemia
(ALL) trials from the Pediatrie Oncology Group (POG)
provides further information.'l Although the number of
criteria doubled in both trial groups over the time period,
the number of criteria in the POG trials (6 to 12) remained
substantially fewer than the number of criteria in the NSABP
trials (22 to 44). Perhaps as a result of differences in
defining eligible subject populations in the two cancer
types, the proportion of patients with ALL enrolled in RCTs
(79%)32 is much greater than the proportion of breast cancer
patients enrolled in trials (3.3-8%) .1,2
Finally, the discrepancy between North American studies
and non-North American studies observed in this review may
indicate that North American RCTs have eligibility criteria
that are unnecessary. North American studies excluded 55% of
subjects due to ineligibility while studies conducted
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elsewhere excluded only 36%. Sorne of the non-North American
studies appear to have used very few eligibility criteria
indeed. Anderson reports that three RCTs of the Danish
Breast Cancer Cooperative Group studying the treatment of
breast cancer with adjuvant therapy contained a minimal set
of criteria ("operable breast cancer with no metastases",
"no medical contraindication to the study treatments" and
"age less than 70,,).n
The inclusion of "no medical contraindication" as an
eligibility criterion may explain why no subjects are
excluded due to 'physician refusal' in the non-North
American studies. But isn't this single criterion really a
proxy for a whole set of criteria made explicit in North
American protocols? Yes and no. Insofar as North American
protocols make explicit with eligibility criteria subsets of
patients for whom the study treatments are contraindicated
(i.e. those patients who would not be treated in clinical
practice), these criteria are identical to the "no medical
contraindication" criterion. These criteria are necessary
(either in an abbreviated or an explicit form) and do not
diminish the applicability of a RCT's results to clinical
practice. North American trials, though, typically exclude
further categories of patients -- patients with, for
example, a history of cancer, or comorbid conditions -- from
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trials: patients who would be treated in clinical practice.
These criteria are not essential -- either to protect
patients from harm or to make the population of patients
more homogeneous -- and have the disadvantage of reducing
the generalizability of a trial's results. Indeed, our
above-mentioned comparison of NSABP and POG clinical trials
revealed that the bulk of the increase in eligibility
criteria over the twenty year period was accounted for by
criteria designed to make the study population more
homogeneous (criteria directed at patient safety remained
constant) . J1
Why do sorne ReTs have unnecessary eligibility criteria?
Begg et al. offer three answers to this question: (1) fear
of excessive toxicity, (2) attempting to attain homogeneity
and, (3) concern over qualitative interaction. 4 Let us
discuss each of these in turn.
Fear of excessive toxicity. Particularly in trials with
toxic treatments, such as cancer chemotherapy trials,
concern over toxicity may motivate trial designers to
exclude subjects thought to be unduly or unusually
susceptible to harm, including those who are old (e.g.
excluding persons >70 years of age), those with abnormal
organ function (e.g. excluding persons with liver enzymes
greater than 1.5 times the upper limit of normal) and those
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with comorbid conditions (e.g. excluding patients with
cardiac disease).' Clearly, subjects for whom one of the
trial treatments is contraindicated must be excluded. But,
as noted above, the necessity of excluding persons thought
to be susceptible to harm from trials is uncertain: the risk
associated with many "toxicity" exclusion criteria is ill-
defined. The lack of information on risk is, indeed, largely
due to the routine exclusion of these groups from RCTs.
The routine exclusion of patient subgroups by
"toxicity" eligibility criteria has a number of detrimental
effects. First, little information exists to guide
practitioners in the treatment of persons in these
subgroups. For example, as a result of the routine exclusion
of persons over the age of 70 from cancer treatment trials,
little information exists on the treatment of cancer in the
elderly.33 Second, unsuspected treatment benefits may remain
undiscovered. Concerns over the risk of haemorrhagic
complications from intravenous thrombolysis motivated most
trials testing thrombolytics in the treatment of acute MI to
exclude persons over the age of 75. 34 Results from the 1515-
2 trial indicate, however, that the benefit from
thrombolysis may be greatest over the age of 75. 3' Finally,
"toxicity" exclusions may have unintended effects in RCTs.
In a review of 214 clinical trials of various therapies in
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the treatment of acute MI, Gurwitz et al. found that 61% of
the trials excluded persons over the age of 75. 35 Since more
women than men survive past the age of 75, the trials with
age-based exclusions had a lower proportion of women
participants. l5
Attempting to attain homogeneity. Begg et al. speculate
that many trial designers have been motivated by the ideal
of the "wet-bench experiment" which utilizes homogeneous
experimental units.' Trial designers commonly attempt to
increase the homogeneity of study population by excluding
subjects thought to have differing prognoses. The laboratory
ideal of homogeneous experimental units cannot, however, be
achieved in the clinical setting where "between-patient
variation is always large relative to th,;! anticipated
treatment effect".' Yusuf et al. point out that this
unavoidable heterogeneity is due to the fact that "aIl
variables that influence an outcome are not known and these
unknown variables can have a substantial impact upon
prognosis" . 36
The solution is not found in defining the eligible
subject population narrowly. Restricting the eligible
population will both diminish the ability of an RCT to
enroll sufficient patients and will reduce the relevance of
the RCT's results to clinical practice. 35 Rather, the answer
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is to randomize large nurnbers of subjects so that those with
differing prognoses will tend to be evenly distributed among
the treatment arms in a RCT."·"
What if circumstances seem not to allow for the
randomization of larger nurnbers of subjects? What if funding
or human resources or both are restricted? The cornbined
approach of minimizing criteria for trial eligibility and
simplifying other aspects of a RCT offers a relatively cost-
free approach to increase trial enrollment. If eligibility
criteria are minimized, the financial and human resource
"cost" per patient is reduced: fewer investigations are
required, less paper work needs to be filled out and the
arnount of physician time required is diminished. J7
Qualitative interaction. As stated above, subgroups of
patients in whom a therapy is known to be harmful must be
excluded from a trial. However, additional groups of
patients are frequently excluded from trials on the basis
that the treatm~nt effect may be in a different direction in
that group (qualitative interaction) or in the sarne
direction but of diminished magnitude (quantitative
interaction).' It seems though that unexpected qualitative
interactions are rare. Yusuf et al. exarnined widely-
differing groups of patients treated with antiplatelet
drugs, beta-blockers and calcium channel blockers and found
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that the direction of effect was the same in all groups.36
Furthermore, groups excluded because of concern over
qualitative effects have, in sorne cases, subsequently been
proven to have benefits similar in magnitude to those of
other trial participants. For example, the concern that late
reperfusion therapy might induce early mortality after acute
myocardial infarction motivated a number of trials of
thrombolytic agents to restrict trial eligibility to those
who presented within 6 hours of the onset of symptoms. Yet,
Yusuf's meta-analysis demonstrated that the treatment
benefit in the 7-24h post-MI group was in fact comparable to
that in the early presentation « 6 hl group.38 Similar
concerns motivated the routine exclusion of patients with
congestive heart failure from ReTs testing the effect of B-
blockers post-MI. It seems though that the reduction in
mortality offered by beta-blocker therapy is similar in
patients with and without heart failure. 36
Even if quantitative interactions are known to exist
for certain subgroups of patients, it may be more efficient
to include them in a trial than to exclude them. When
efficiency is measured in terms of trial duration, this is
not difficult to understand. By excluding these subgroups,
the pool of subjects eligible for the trial is reduced and,
hence, the rate of enrollment in the trial is slowed. Thus,
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gains in terms of enrolling only subjects likely to have a
large positive outcome can be quickly lost to slow rates of
enrollment in the RCT. Buyse reports the results of an
armchair experiment in which the efficiency of including a
poorer prognosis group of patients in a trial is calculated
with varying degrees of qualitative interaction in the poor
prognosis group and varying proportions of poor prognosis
patients in the patient population as a whole. 39 Buyse found
that including the poor prognosis group increases efficiency
across a broad range of assumptions. 39
It is clear from the res~lts of this review that any
attempt to improve the proportion of patients enrolled in
randomized controlled trials ought to address the issue of
subject eligibility. The most obvious and efficient solution
would be for RCT designers to embrace the ideal of the
broad-based, pragmatic randomized controlled trial. By
mirroring clinical reality as closely as possible, a RCT
will maximize the usefulness of its results to clinicians
and thus. will optimize the impact of the trial on clinical
practice. Furthermore, by utilizing a minimal set of
eligibility criteria. the RCT will maximize the pool of
eligible subjects available for trial enrollment and thus.
decrease the duration of the enrollment phase of the trial.
In keeping with the ideal of a minimal set of eligibility
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criteria. when individual eligibility criteria are required.
they ought to be individually justified to highlight their
necessity. Critically addressing the issue of subject
eligibility will. when used in concert with the approaches
to the enhancement of enrollment outlined above, maximize
patient enrollment in ReTs .
• •
Table 1.
Reason for non-participation
Other
Study Sa!"ple No protocol Physician Subject exclusion Enrolled
Study population Slze available Ineligible refused refused orunknown in trial
Number (percentage) N (%)
Greco cancer 202 89 (44) 32 (16) 14 (7) 33 (16) 0(0) 34 (17)
(l980)t patients
McCusker cancer 454 112 (25) 196 (43) 19 (4) 8 (2) 6 (1) 113 (25)
(1 982)t patients
lung 347 81 (23) 108 (31) ? ? 49 (14) 31 (9)
cancer
Lee radiotherapy 1103 703 (64) 137 (12) 118 (II) 21 (2) 0(0) 124 (II)
(l983)t patients
Degg cancer 3534 774 (22) 1665 (47) 287 (8) 105 (3) 66 (2) 637 (18)
(1 983)t patients
Hunier cancer 44156 26383 (60) 9486 (22) 2859 (6) 1794 (4) 392 (1) 3242 (7)
(l987)t patients
Anderson breast 18487 1565 (9) 4827 (26) 0(0) 234 (1) 504 (3) 11357 (61)
(1988) cancer
Jack breast 324 177 (55) 84 (26) 0(0) 23 (7) 0(0) 40 (12)
(1990) cancer
Dertelson ovarian 716 104 (15) 256 (36) 3 (0) 13 (2) 3 (0) 337 (47)
(1991) cancer
Unweighted mean proportion § 45 9 9 36
Weighted mean proportion § 43 8 6 2 41
• •
Table 1. Group l studies: Studies reporting on the enrollment experience of a population
cohort to 2 or more randomized controlled trials.
Legend:
t - study reporting enrollment to North American based ReTs;
§ - proportion of subjects for whom a trial was availabla for their type and stage of
disease lie. denominator is 'sample size' minus 'no protocol available').
• •
Table 2.
Reason for non-participation
Other
Study Sample Wrongstage Physician Subject exclusion Enrolled
Sludy population size ofdisease Ineligible refused refused orunknown in trial
Number (percentage) N('k)
Lee lung 653 434 (66) 142 (22) 34 (5) 2 (1) 0(0) 41 (6)
(1980)t cancer
CASS heart 16626 11838 (71) 2689 (16) 910 (5) 369 (2) 40 (1) 780 (5)
(1984)t disease
Kronborg rectal 1369 508 (37) 341 (25) 2 (0) 9 (1) 24 (2) 485 (35)
(1988) cancer
Ward stomach 1209 93 (8) 310 (26) ? ? 24 (2) 249 (21)
(1992) cancer
Greil affective 6213 2826 (46) 2399 (39) 0(0) 393 (6) 217 (3) 378 (6)
(1993) disorders
Unweighted mean proponion § 58 7 4 2 29
Weighted mean proponion § 60 10 8 3 19
•Table 2. Group 2 studies: Studies reporting the enrollment experience of a population
cohort to a single randomized controlled trial.
Legend:
t - study reporting enrollment to North American based ReT;
§ - proportion of subjects for whom a trial was available for their type and stage of
disease lie. denominator is 'sample size' minus 'wrong stage of disease').
•
•Table 3.
Reason for non-participation
Other Enrolled
Study Sample Physieian Patient exclusion in trial
Study population size Ineligible refused refused orunknown
Number (percentage) N('Ib)
Lucas breast 57 41 (72) 5 (9) 8 (14) 3 (5) 0(0)
(1984) cancer
Martin cancer 2687 1738 (65) 284(11) 228 (8) 0(0) 437 (16)
(l984)t patients
Winger anaplastie 197 119 (60) 0(0) 23 (12) 0(0) 55 (28)
(1989)t glioma
Muller acule 49556 33230 (67) ? ? ? ?
(1990) Ml
Fenliman breasl 216 129 (60) 4 (2) 6 (3) 0(0) 77 (35)
(1991) DelS
Hjonh muhiple 255 60 (24) 0(0) 15 (6) 0(0) 180 (70)
(1992) myeloma
Morris acule 2(X)" 87 (44) ? ? ? ?
(1993) slroke
191 (96) ? ? ? ?
Unweighted mean proponion § 56 4 9 30
Weighted mean proponion § 61 9 8 0 22
•
• •
Table 3 Group 3 studies: Studies reporting the enrollment of a cohort for whom a trial was
available for their type and stage of disease in a single randomized controlled trial.
Legend:
t - study reporting enrollment to North American based RCT;
* - two-hundred patients in an acute stroke unit were assessed for their eligibility for
two RCTs that had not yet begun to enroll patients;
§ - proportion of subjects for whom a trial was available for their type and stage of
disease (ie. denominator is 'sample size').
11
Figure 1.
••
Figure 1. The typical fate of 100 potential subjects for a
ranQ~mized controlled trial .
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Bridging section
The second chapter has addressed two of the three
empirical questions posed in chapter 1. The first question
asked: Is a large proportion of patients with a given
disease treated in clinical trials? Although relatively
little empirical information exists on this point, it is
clear that for the majority of cancers only a small
proportion of patients are treated in clinical trials. As a
result, we cannot be certain that the results of trials are
widely applicable to clinical practice. When the proportion
enrolled is small, trial participants may differ for the
patient population at large in clinically important ways.
The second question was: Are subjects randomly selected
from the patient population for participation in clinical
trials? The answer to this question is clearly "no".
Protocol factors, physician factors and patient factors have
all been cited as being barriers to clinical trial
enrollment. The empirical study in chapter 2 attempted to
quantify the relative selective force that each of these
exerts on trial enrollment. Overall, 32% of subjects for
whom a trial was available for their type and stage of
disease (and who themselves were available for enrollment)
were entered into clinical trials. Eligibility criteria were
the largest barriers to trial enrollment, eliminating 53% of
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potential subjects. Physician and patient factors were
relativ~ly less important, each accounting for roughly 7% of
potential subjects (1% were excluded for other reasons) .
Since eligibility criteria frequently exclude persons
on the basis of clinically important factors -- demographic
and prognostic factors, we must be concerned that clinical
trial participants may differ in important ways from the
population in clinical practice. As such, we must be
concerned that the results of trials on such a select
population may not be widely generalizable.
The third chapter addresses the issue of the
comparability of trial participants and non-participants
directly. If trial participants do indeed differ in
important ways from trial non-participants, the
generalizability of trial results may not be widely
applicable. The results thus far would suggest that a
solution to this problem will include changes to criteria
for trial eligibility .
••
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Chapter 3:
Are randomized controlled trial participants comparable to
non-participants?
-- A review of the empirical literature .
••
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Abstract
Introduction. The importance of a randomized controlled
trial (RCT) is, in part, a function of how widely applicable
its results are to clinical practice. The literature gives
us reason to be concerned that the population treated in
clinical trials may differ in clinically important ways from
the patient population in general: first, only a small
proportion of patients are treated in trials and, second,
barriers to trial enrollment, such as eligibility criteria,
exist. We set out to systematically examine empirical
studies that compared trial participants and non-
participants.
Methods. Nine variables of interest -- demographic,
prognostic and outcome variables -- were defined a priori
for this study. Empirical studies of trial participants and
non-participants that reported on at least one variable of
interest were retrieved from the Medline (1966-1994) and
Cancerlit (1983-1994) databases.
Results. In all, 19 studies were retrieved from the
literature, the majority of which were cancer clinical
trials. RCT participants were significantly younger than
non-participants and may have had better performance status
scores. These differences were not seen in studies in which
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the comparison group included only eligible non-
participants, suggesting that eligibility criteria were the
cause. Participants also survived longer than non-
participants. This significant survival difference remained
in six of the seven studies that adjusted survival for
important covariates.
Discussion and Conclusion. Important differences exist
between patients studied in cancer clinical trials and the
patient population at large. The generalizability of RCTs to
clinical practice is therefore suspect. Attempts to remedy
this situation will need to address the role that criteria
for trial eligibility have in unduly narrowing the study
population in trials .
••
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Introduction
Any writer who is worth her salt knows that one has to
remember for whom one is writing; a text that is meaningful
for one audience may not be meaningful. or for that matter
interesting, for another. As with skilful writing, so too a
randomized controlled trial has an audience who must be
considered at the time a trial is designed. Since the
importance of a RCT is measured by its impact on clinical
practice. trial designers must carefully consider what
population of patients a trial outcome is intended, at least
ideally, to affect eventually. Decisions made at the time of
a trial's design will have a large impact on the scope of
the applicability of the trial's results. If the trial
includes therapeutic interventions or imaging procedures
that are only available in a few technologically-advanced
tertiary care centres, the generalizability of the trial's
results may be limited. Criteria for trial eligibility will
also influence the applicability of a trial. Restricting the
study population to only those at very high risk of an
outcome -- such as mortality or myocardial infarction, while
potentially advantageous from the point of view of reducing
the required sample size for a trial, will limit the
general'Lzability of the trial's results. Thus, the intended
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impact of a RCT ought to guide decisions made at the time of
trial design.
The related issues of trial generalizability and
selection of subjects for trials are much disputed in the
literature on research design. Following Schwartz and
Lellouch's' distinction between approaches to ReT design. we
might characterize this debate as being between those
arguing for what Feinstein2 refers to as fastidious
(scientific. narrow) trials and those calling for pragrnatic
(clinically relevant. broad) trials.
Propon~nts of fastidious trials argue that it is
important to reduce variability in a trial in order to
attempt to isolate the effect of the treatment on the
outcome measure and hence, relatively homogenous subgroups
of patients ought to be studied in RCTs.' Once a treatment
has been demonstrated to be effective, the effect may be
, ..•.. ·ned to have a biological basis, or "biological effect H ,
which, barring evidence to the contrary, may be presurned to
be broadly generalizable. 4 The results of RCTs may, thus. be
applied to population groups not included in a trial, unless
evidence (or strong theoretical basis) exists that a given
population group may respond differently to the treatment.
Supporters of pragrnatic trials counter that homogeneity
of a study population is an unachievable ideal when dealing
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with human subjects. 5 Patient-to-patient variability will
remain the largest source of variability in most RCTs. 5 This
fact is mirrored in clinical practice: while a given
disease, such as metastatic breast cancer, has a definable
median survival, the prognosis of an individual patient (and
her response to treatment) is difficult to predict
accurately. The answer to this problem, the clinical-trial
pragmatists argue, is to accrue large numbers of patients to
trials and this suggests relaxing criteria for trial
eligibility.6 The results of such a trial will be based on a
broad-patient population, one that is likely to be
reflective of clinical reality. 7 The results of such a trial
are, therefore, broadly generalizable.
Recently, in the United States, politicians and patient
activist groups have entered the fray. Responding to the
alleged under representation of women8•9 and minorities 'O in
clinical trials, recent regulatory changes, including the
"NIH Guidelines on the Inclusion of Women and Minorities as
Subjects in Clinical Research"," require the inclusion of
representative numbers of individuals from these groups in
government funded biomedical research. 12 •1J In addition, the
NIH Guidelines require that, in the absence of strong a
priori evidence one way or the other, the analysis of a
trial's results include subgroup analyses to examine
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possible differential treatment effects in racial/ethnie and
gender subgroups." The subgroup analyses, though, are
primarily intended as hypothesis generating and, as such,
"the trial will not be required to provide high statistical
power for each subgroup"." Only in the case in which strong
a priori evidence exists that a given group will respond
differently to a treatment is the trial required to address
this as a primary question in the study, that is, to ensure
a comparison with sufficient power for that purpose."
These changes in U.S. Government policy were motivated
by a number of factors, including concerns that the
exclusion of women and racial/ethic minorities from clinical
trials may represent discrimination and, furthermore, that
these groups may be deprived of any benefits associated with
trial participation. Clearly, though, concern over the
generalizability of RCTs that fail to include (adequate
numbers of) women and racial/ethnie minorities also
motivated thF.3e changes:
Since a primary aim of research is to provide
scientific evidence leading to a change in health
policy or a &tandard of care, it is imperative to
determine whether the intervention or therapy
being studied affects women or men or members of
minority groups and their subpopulations
differently. To this end, the guidelines published
here are intended to ensure that aIl future ~IIH­
supported biomedical and behavioural research
involving human subjects will be carried out in a
manner sufficient to elicit information about
individuals of both genders and the div~rse racial
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and ethnic groups and, in the case of clinical
trials, to examine differential effects on such
groups.1l
In essence, the NIH's position is that only trials that
contain adequate numbers of women and minorities can be
considered generalizable to these populations (even in the
absence of a priori data to indicate that a differential
effect in these groups is likely). As such, the NIH's stand
represents a clea~ r~jection of the "biological effect"
model of inference to populations of patients more
heterogeneous than those actually studied.
Subjects who end up on RCTs may, of course, differ from
clinical populations in ways other than gender and
race/ethnicity. In a review of factors that influence
accrual to RCTs, Gotay describes a range of characteristics
that differentiate cancer trial participants from non-
participants." According to Gotay, subjects who enter
trials tend to be younger, wcigh more, have better
performance status and have higher socioeconomic status tr..an
non-participants. She points out that these differences a~e
caused by obstacles to trial accrual, including crite~~a for
trial eligibility, physician sel~ction and patient
factors. '4 A l:ecent review of empirical studies on
enrollment in RCTs indicates that criteria for trial
eligibility represent the largest selective pressure on
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trial enrollment. 15 Of subjects for whom a trial was
available for their type and stage of disease, 32% were
enrolled in a RCT, 53% were ineligible for trial
participation, 7% were excluded due to physician refusaI, 7%
refused to participate, and 1% were excluded for other
reasons .15
A review of the literature was undertaken to attempt to
address the following questions: Is there evidence that
trial participants differ from non-participants? If such
differences exist, are they, as suggested above, the result
of criteria for trial eligibility? Can an approach similar
to that outlined ~n the NIH Guidelines be applied to rectify
the situation?
Methods
Publications of empirical st~dies reporting on
differences between randomized controlled trial participants
and non-participants were retrieved through searches of the
Medline and Cancerlit databases (Medline: 1966 through
October, 1994; Cancerlit: 1983 through September, 1994). The
following search terms were used: "clinical trials",
"prognosis" , "patient participation", "eligibility
determination" and "registries". The results of these
searches were supplemented with articles referenced in the
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bibliographies of relevant articles and other published
sources. Empirical studies were included in this review if
they reported results of at least one variable of interest
(listed infra) for both subjects enrolled in a randomized
controlled trial and trial non-participants. Reports of
randomized controlled trials for any disease site reported
in the English literature were included in this review.
Since eligibility criteria are thought to be a major
cause of differences between trial participants and non-
participants, comparisons between RCT participants and
eligible non-participants are reported separately from
comparisons of trial participants and unselected (eligible
and ineligible) non-participants. Empirical studies that
reporLed both comparisons for a single RCT are reported
twice, once in each category. If criteria for trial
eligibility are indeed the major cause of differences
between trial participants and non-participants, differences
between participants and non-participants should be
restricted to the comparison involving unselected non-
part1cipants.
The following basic information was recorded for each
empirical study: first author, year of publication, study
disease, and sample size. The sample size was defined as the
number of ~atients in the ReT plus the number of non-
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participants included in the comparison. Thus, a study
reporting both comparisons of interest (RCT participants
versus eligible non-participants and RCT participants versus
unselecced non-participants) will have two different sample
sizes.
The variables of interest selected for this study were
chosen a priori on the h~sj.s that they (1) were c1inically
important, (2) included demcgraphic, prognostic and outcome
variables, and (3) were likely to be reported in the
published report of a RCT. The following variables were
selected: age, gender ratio (male/female), race ratio
(Caucasian/non-Caucasian), socioeconomic status, extent of
disease, performance status, crude survival, and survival
adjusted for covariates. Information on each of these
variables was recorded, if available, from each empirical
study included. A difference, either "in favour" of RCT
participants or trial non-participants, for each of the
variables was defined as a statistically significant
difference if reported a~ such in the journal article. In
sorne cases no statistical test was reported in the
publication, but sufficient information was present for an
unpaired t-test or a chi-square test to be done (as
appropriate) . In the few cases in which neither a
statistical test was reported nor could one be done based on
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reported figures, a difference was reported as being present
if the authors concluded that the observed difference was
clinically important. If none of these conditions obtained,
it was concluded that no Jifference existed between ReT
participants and non-participants for that variable. The
direction of the difference (if present) was recorded, but
not the magnitude of the differeüce. The studies included in
this review cover a heterogeneous group of diseases and,
therefore, the magnitude of difference, e.g. months of added
survival, was not likely to be meani~gfully comparable
across studies.
The proportion of studies in which a difference was
found (the denominator being the total studies that reported
information on a given variable) is reported fo~ each of the
variables. Only descriptive statistics are reported.
Results
Nineteen empirical studies that satisfied the criteria
for eligibility for this study were retrieved from the
literature. The majority of the studies involved persons
with cancer (16/19 studies), two studies involved patients
with cardiovascular disease, and one study included persons
with psychiatrie disease (tables 1 and 2). Two studies
reported both comparisons of interest and, hence, are
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reported in each category of study. Nine studies (published
between 1979 and 1993) reported comparisons of RCT
participants and eligible non-participants (table 1). In
total, the nine studies documented the characteristics of
6,620 individuals. A total of twelve studies (published
between 1983 and 1992) document comparisons of RCT
participants and unselected non-participants (table 2).
These twelve studies reported on 71,820 subjects.
Studies that compared trial participants with eligible
non-participants are listed in table 1.16.1?IR.19.20.21.22.2).2. No
consistent pattern of differences is seen amongst the
demographic variables (table 1). Of the seven studies
reporting on age, five (5/7) found no differe~ce between the
two groups and two (2/7) reported that ~ubjects on trial
were younger. Five of the six studies (5/6) reporting on
gender found no difference between the two groups, while one
(1/6) found that males were more likely to be enrolled in a
RCT. Both of the studies (2/2) reporting on racial
characteristics found no difference between study
participants and non-participants. Of the two studies
reporting on socioeconomic status, one (one of two) reported
that trial participants had a higher socioeconomic status
and the other (one of two) found no difference between the
two groups.
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Similarly, there is little evidence for a consistent
pattern of difference in prognostic or survival variables
(table 1). Of the five studies that reported on extent of
disease, four (4/5) found no difference between the groups,
while one (1/5) reported that trial participants had more
extensive disease. The two studies that reported a
difference with regard to performance status were evenly
split: one (one of two) reported that trial participants had
a higher (better) performance status; the other (one of two)
reported that non-participants had a higher performance
status. Six studies reported on crude (unadjusted) survival:
four (4/6) found no difference between the two groups; two
reported a survival advantage for RCT participants. Four
studies reported figures for survival adjusted for various
covariates. Though two studies (2/4) found no difference,
two reported that RCT participants survived longer than non-
participants.
Overall then, no consistent pattern of differences was
observed in comparisons of RCT participants and eligible
non-pa~ticipants. At least with respect to the variables
surveyed, RCT participants are comparable to eligible non-
participants. If substantial differences were introduced by
factors' .her than criteria for trial eligibility, for
example, physician selection and patient refusal of informed
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consent, we would have expected to find differences in this
comparison. We did not. It is unlikely, therefore, that
these other factors have a substantial impact on shaping the
characteristics of trial participants.
Studies that compared RCT participants with unselected
(eligible and ineligible) non-participants are listed in
table 2. 25 ,26,27,28,29,30,31,21,32,33,23,34 Substantial differences were
noted amongst the demographic variables reported on (table
2). Of the nine studies that reported the age of subjects,
seven (7/9) reported that RCT participants were
significantly younger than non-participants; two (2/9)
reported no difference. One of the two studies that found no
age difference between the two groups was a study of
childhood leukemia that used an age cutoff of 15 years. 25 It
is of note that all of the studies reporting on gender (6/6)
and race (2/2) found no difference between the groups. No
study reported on socioeconomic status.
Unfortunately, too few studies reported on prognostic
variables for there to be a clear indication of a pattern
(table 2). All three studies (3/3) that looked at extent of
disease found no difference between trial participants and
unselected non-participants, Both (2/2) studies that
examined performance status found that trial participants
had higher scores and, hence, a better performance status.
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The data on outcome variables indicate that trial
participants sur"ived longer than non-participants (table
2). All nine studies (9/9) reporting crude survival found
that RCT participants had higher survival rates than non-
participants. All five studies (SIS) that reported on
survival adjusted for covariates found a survival advantage
for triai participants.
Substantial differences, then, were found between RCT
participants and unselected non-participants. Trial
participants tended to be younger and survive longer than
non-participants. Also, they may have had a better
performance status than non-participants (although only two
studies =eported this). Thus, RCT participants are not
comparable, in important ways, with unselected non-
participants. As these differences were not seen in
comparisons of RCT participants and eligible non-
participants, it is likely that these discrepancies are the
,esult of criteria for trial eligibility.
The issue of survival of RCT participants is worthy of
further attention. What might account for the survival
advantage observed for RCT participants? Table 3 lists the
results of the seven studies that both reported a crude
survival advantage for trial participants and then adjusted
survival for various covariates. The table lists the
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method(s) used in the adjustment, the covariates adjusted
for and the resulting adjusted survival comparison. If trial
participants differ from non-participants in terms of age
and other prognostic variables, we might expect them to have
a better survival than non-participants on this basis alone.
Although sorne of the studies adjusted for age (5 studies),
extent of disease (4 studies) and performance status (1
studYl, all but one of the studies (6/7) continued to show a
survival advantage for trial participants (all of the six
"positive" studies adjusted for age or extent of disease,
two adjusted for both). A number of possibilities emerge
based on this. First, it is possible that the survival
difference is indeed due to prognostic differences between
the two groups and that we are just not very good at
correcting for these differences. Noting from table 2 that
many variables were not examined, the answer may lie in
filling in the blanks in the table. A second possibility,
though, is that RCT participation may, in and of itself,
confer a survival advantage on participants. RCTs offer more
rigorous protocols for treatment administration and follow-
up. It is possible that these factors may translate into a
survival advantage for participants.
Finally, in keeping with the theme of this paper, it
should be emphasized that given the small number of studies
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included in this review, the generalizability of these
findings is uncertain. As noted above, the majority of
studies involved cancer patients and, thus, the findings are
most immediately applicable to cancer trials. The small
number of non-cancer studies make the validity of an
inference beyond the cancer trial setting dubious.
Discussion
Given the political and regulatory attention recently
devoted to the exclusion of women and racial/ethnic
minorities from clinical trials, it is surprising that none
of the studies in our review found significant differences
with respect to gender or race. Ind@ed, we did find that an
important demographic difference exists between trial
participants and non-participants: patients who end up on
trials tend to be younger. Can we make sense of this finding
in light of the literature on the exclusion of women from
trials?
While there is evidence that women have been excluded
from phase III clinical trials for sorne categories of
disease, evidence for a general phenomenon is lacking. A
review by the General Accounting Office (GAO) of New Drug
Applications to the Food and Drug Administration (FDA)
(1988-1991), showed that women were indeed under represented
••
97
in phase II and phase III trials of new cardiovascular
agents." There was no evidence, however, of the exclusion of
women for any other class of agents included in the study.
Bird reviewed clinical research published in the Journal of
the American Medical Association in 1990 and 1992 and found
that, in studies of non-gender-specific diseases, women were
under represented 2.7 times as often as men. 9 These findings
were largely explained, though, by the substantial under
representation of women in cardiovascular trials. 9
Is there a connection between the exclusion of women
from cardiovascular trials and the exclusion of older
patients from trials? It seems that there may be one.
Gurwitz et al reviewed 214 RCTs of the treatment of
myocardial infarction and found that the proportion of women
included in trials was strongly associated with the presence
of age-based exclusion criteria in the trial. 35 RCTs with
age-based exclusion criteria had a significantly lower
proportion of women enrolled in the study. This is, of
course, a reflection of the fact that women get heart
disease later in life than men; excluding older persons from
cardiovascular trials, therefore, differentially excludes
women from trials. 50 it seems that gender differences in
cardiovascular trials may, at least in part, be explained by
age-based exclusions rather than gender-based exclusions per
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se. The results of our study suggest that under
representation of the elderly may be more wide-spread than
gender under representation. If true, the focus of the NIH
Guidelines seems misplaced.
The exclusion (or under representation) of groups of
patients from ReTs can have serious consequences. The
exclusion of the elderly, particularly from cancer trials,
has lead to a serious lack of information regarding the
proper treatment of older persons with cancer, the
population most heavily burdened with the disease. 36 A
number of stud~es have demonstrated that older persons with
cancer tend to be under-treated. 37 • 38 This phenomenon may, in
part, be due to the paucity of clinical trials addressing
the treatment of cancer in the elderly. 39.'0
eIder persons with cancer may differ from younger
persons with cancer in clinically i~portant ways. eIder
persons have long been thought to be more susceptible to
side eLfects from chemotherapy and other cancer
treatments.'l It is certainly true that sorne chemotherapy
agents induce more frequent or more severe side effects (or
both) in older persons.'2 Also, important biological
differences in tumours may be related to age. For example,
cancers of the colorectum, lung, prostate and bladder have
been reported to be of a less differentiated histological
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grade in older patients." The net effect of these
differences is that response to cancer treatments in the
elderly is diverse -- sorne cancer types showing better
responses (e.g., colon cancer) ,44 sorne similar responses
(e.g., lung cancer),45 and sorne worse responses (e.g., acute
leukemias, lymphomas, and Hodgkin' s disease) 46.47.48 than
cancers in younger patients. These differences are not a
priori predictable from studies done solely on younger
cancer patients.
The heterogeneity in response to treatment in the
elderly highlights the basic fallacy with the "biological
effect" model: even if biological responses (of tumours,
say) are generalizable from narrow study populations, other
host factors may differ greatly in subgroups of the target
population leading to differing net responses to treatment.
(An aggressive treatment regimen that eradicates the cancer
but kills the patient is of little benefit.) Study
populations will need to be broad-based to examine these
issues adequately.
But how many subjects from a given subgroup need to be
included in a trial in order to provide a sound basis for
the treatment's generalizability to clinical practice? l
take it as uncontroversial that if no subjects from a group
defined by sorne factor of potential biological (or clinical)
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importance are inc1uded in a trial, no valid inference can
be made regarding the treatment's efficacy in that group."
But, is the inclusion of a representative proportion of
individuals from a given group in a trial a sufficient basis
to conclude that the treatment is proven effective in (i.e.,
can be generalized to) that group? Or, must we prove the
effectiveness of a treatment for each group by means of a
formal demonstration of a statistically and clinically
significant difference in favour of the study trea~ment?
A conservative attempt at a solution to this problem
might begin by considering the plausibility of the following
premise: A trial large enough to allow for a separate and
sufficiently powerful comparison for each group of
biological or clinical interest is to be preferred over a
smaller trial designed around the average (overall) effect.
Clearly, depending on the number of groups of biological or
clinical interest, the former trial will be much larger
indeed than the latter. Consider the example given by Yusuf
et al. so : Suppose one is planning a RCT to examine the
effect of B-blockers on mortality post-myocardial
infarction. The expected mortality in the control group is
approximately 10% and the expected mortality in the
experimental arm is 7.5% (a relative mortality reduction of
25%). If power is set at 90% and significance level at 0.01,
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then just under 4000 subjects will be required in each of
the two study arms, a total of about 8000 subjects. Suppose
now that we wish to examine the effect of the treatment
separately in two groups, anterior infarctions and inferior
infarctions. Holding aIl else constant, the trial will now
require 16000 subjects. Of course, there may be many other
groups of interest -- women versus men, older versus
younger, class of cardiovascular disability (4 groups)
and the sample size of the trial will increase proportional
to the product (2x2x4) of the number of categories of
interest. Clearly, the feasibility of such an approach to
trials is questionable -- a single trial may consume aIl the
resources that a funding agency has available.
But there is an even more vexing problem with this
approach. If we assume that the treatment effect is constant
across the groups of interest (and that accrual to each of
the groups is uniform), then an analysis for average effect
will reach statistical significance long before the
comparisons in the individual groups. This will leave the
investigators in the uncomfortable position of "knowing"
that on average the experimental treatment is superior to
the control treatm~nt, and yet being forced to continue the
trial to allow this effect to be proven in each of the
subgroups. As such, continuing the trial in this
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circumstance seems to violate the Declaration of Helsinki,
the most influential international statement on the ethics
of research, which requires that: "In any medical study,
every patient -- including those of a control group, if any
-- should be assured of the best proven diagnostic and
therapeutic u,ethod". 51
Underlying this dilemma is a basic question of medical
epistemology -- when has a treatment been proven effective?;
when ought/must we stop a trial? -- that gets at the heart
of the ethical permissibility of clinical research. One
approach to this problem is to examine the conditions that
must exist ab initio for a trial to be ethical; if and when,
during the conduct of the trial, these conditions no longer
obtain, the trial must be stopped.
There is a consensus that at the beginning of a ReT
comparing two or more treatments an honest null hypothesis
must exist. 52 In other words, uncertainty must exist as to
the relative merits of the treatments being tested in the
trial. 53 Sorne authors have argued that this means the
treatments in a trial must be precisely balanced -- referred
to as "theoretical equipoise" -- that is, no empirical
grounding for a preference for one treatment over another in
a trial can exist. 54 As Freedman has correctly pointed out,
this understanding of equipoise is ail too fragile: the fate
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of a single patient in a RCT could throw the balance in
favour of one treatment or the other. thus. requiring that
the trial be stopped. 55 Freedman has persuasively argued for
a different understanding of equipoise termed "clinical
equipoise". Clinical equipoise exists when there is "an
honest. professional disagreement among expert clinicians
about the preferred treatment".55 A trial is permissible if
the following conditions obtain:
[A]t the start of the trial, there must be astate
of clinical equipoise regarding the merits of the
regimens to be tested, and the trial must be
designed in such a way as to make it reasonable to
expect that. if it is successfully concluded,
clinical equipoise will be disturbed. In other
words. the results of a successful trial should be
convincing enough to resolve the dispute among
clinicians . 55
If the yardstick of a successful (and ethicall RCT is
its ability to settle the dispute with regard to treatment
preference among expert clinicians, then the need for an
overall demonstration of the superiority of one agent over
another versus the demonstration of superiority in a set of
clinical relevant subgroups will depend on the skepticism in
the expert community with regard to the universal
applicability of the treatments to a patient population.
Since medical practice is evidence based. this skepticism
will largely be a function of the existence of evidence (or
substantial theoretical considerations) that one or more of
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the treatments is 1ikely to have substantially different
effects in one or more subgroups. In the absence of strong
evidence for such a differential effect, l contend, the
demonstration of the superiority of one treatment in the
aggregate is likely to be sufficient to resolve the
disagreement among expert practitioners. Since, at this
point, clinical equipoise is disturbed, the conditions for
the ethical permissibility of the trial have been altered
and, hence, the trial must be stopped. 56 One treatment is
now (at least in potentiol held by expert practitioners to
be superior and therefore continuing to enroll subjects to
the other treatment arms would be unacceptable since they
would be deprived of the "best proven ... therapeutic
methods" .
If, however, strong evidence exists that a subgroup of
the patient population may respond substantially differently
-- perhaps the group is thought to be more likely to suffer
serious adverse effects or, for sorne reason, is thought less
likely to benefit from the treatment -- from the rest of the
population, the ReT ought to be designed to be sufficiently
powerful to convincingly answer the question for each of the
groups in question. The demonstration of an advantage for
one treatment in the aggregate is, in this case, not likely
to sway practice; thus, the trial ought to be continued
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until the question is answered for these groups. Since, at
this point in the trial (i.e., when only proof for an
average effect exists), clinical equipoise has not been
disturbed, and, by definition, no patient is disadvantaged
in terms of their medical treatment by the trial's
continuation. Indeed, since it is a characteristic of an
ethical trial that the "results of a successful trial should
be convincing enough to resolve the dispute", it would be
unethical to stop the trial prematurely.
What is the proper place for subgroup analyses in the
first of these two scenarios, i.e., when no strong evidence
exists for a different effect? A number of excellent reviews
of the use and interpretation of subgroup analyses in those
trials designed around the investigation of an aggregate
effect have recently appeared.SO.S7.S8 While the reader
interested in an in depth treatment of the subject may
consult these sources, several brief points ought to be made
here. The first is that the average effect across subgroups
is the most reliable indicator of the effect of a treatment.
Thus, if the overall result of the trial is negative,
subgroup analyses are to be discouraged. Conversely, if the
overall result of a trial is positive, i.e. the experimental
treatment is shown (overall) to be superior to the standard
treatment, the absence of a statistically significant effect
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in sorne subgroups should not be interpreted as a lack of
efficacy in those subgroups since the comparisons are likely
to be substantially under-powered. Returning to our example
of the 8-blocker trial with 8000 subjects enrolled, if the
true effect of the treatment is a 25% mortality reduction
and this is true for the subgroups of anterior and inferior
myocardial infarctions. an analysis done sepërately for each
of the two subgroups will only have a power of 56%. Thus,
assuming that the subgroup analyses are independent of each
other. there ois only a 31% chance that both subgroup
analyses will conclude that the treatment is effective.
Subgroup analyses should be understood as being useful for
generating hypotheses for future study.
Much of what we have concluded regarding the
interpretation of treatment effects for subgroups of the
patient population is mirrored in the "NIH Guidelines on the
Inclusion of Women and Minorities as Subjects in Clinical
Research". And as such. an approach like that outlined in
the NIH Guidelines could be used to approach clinical
research in general. In summary the approach would involve
the following:
• Phase III clinical trials ought to include subjects who
are as representative of the population in clinical practice
as possible. As eligibility criteria seem to be the major
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cause of a lack of representativeness, the set of criteria
chosen should be minimized -- the fewer criteria, the
better. The explicit justification of each criterion will
help to emphasize its necessity .
• When strong evidence for a different effect of a
treatment in a clinically relevant subgroup of patients
such as women, older persons or Afro-Americans -- sufficient
subjects ought to be accrued to enable the question of the
treatment's efficacy to be answered separately for that
group. Typically, this will require a that a trial be
substantially larger. It must however be recalled that in
these circumstances, a smaller trial is unlikely to change
clinical practice for aIl groups of patients .
• If there is no strong evidence a priori for a different
effect in any clinically relevant patient group -- and l
expect this circumstance will be the rule -- the use of
subgroup analyses in trials studying the aggregate effect is
still to be encouraged. These analyses, though, should be
understood as hypothesis generating and, as discussed above,
the temptation to treat their results as conclusive should
be avoided.
l would be remiss in my duties if l did not comment on
the survival differences observed between trial participants
and unselected non-participants. In the cancer literature,
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it has long been suggested, but never definitively proven,
that subjects treated in ReTs do better. Stiller, both in an
editorial in the British Medical Journal59 and in a more
thorough review elsewhere,60 has suggested that the
treatments given to cancer patients on trial and the fact
that care is usually given in a tertiary centre both
contribute to improved survival. Our results clearly support
the assertion that trial participants enjoy better outcomes
that unselected non-participants. Whether though this is due
to trial participation per se or is a mere reflection of the
selective effect of other factors such as eligibility
criteria, however, we cannot say. On the one hand, the fact
that only two of six studies that compared trial
participants with eligible non-participants showed this
difference suggests that the survival advantage may be in
large part due to a selective effect. On the other hand, the
failure of adjustment for well-known prognostic variables to
correct for observed survival differences argues for an
advantage above and beyond a mere selective effect. The
issue has not been solved by this study and awaits
resolution by a more comprehensive approach .
• •
Table 1.
Study Sample
Study population size Demographie variables Prognostic variables Outcome variables
gender race socioeconomic eXlenlof performance crude survival adjusted
age ratio ratio status disease stalus survival for covariales
Lennox childhood 202 0 0 0 0 0 0 + +
(1979) nephroblasloma
McCusker lung cancer 174 = = = + = = 0
(1982)
CASS coronary anery 2095 = = = = = 0 = =
(1984) disease
Anlman sarcoma 90 = = 0 0 + 0 0 +
(1985)
Smith coronary anery 1484 + 0 0 0 0 0 0
(1988) disease
Winger anaplastie glioma 78 = 0 0 0 0 + = 0
(1989)
Bertelson avarian cancer 481 0 0 0 0 = 0 + =
(1991)
Ward stomach cancer 710 = 0 0 = 0 = 0
(1992)
Greil affeclive 1306 = = 0 0 0 0 0 0
(1993) disorders
•Table 1. Summary of studies comparing RCT participants and eligible non-participants.
•
Legend:
+ - (compared to non-participants) RCT participants were reported to be older, more
likely to be male, more likely to be white, of higher socioeconomic status, have more
extensive disease, have a higher performance status, or be more likely to survive;
- (compared to non-participants) RCT participants were reported to be younger, more
likely to be female, more likely to be non-white, of lower socioeconomic status, have
less extensive disease, have a lower performance status, or be less likely to
survive;
= - no difference between the two groups;
o - information not reported on in article.
• •
Table 2.
Study Sludy S~ple
population Size Demographie variables Prognostic variables Outcome variables
gender race socioeconomic extent of performance crude survival adjusted
age ratio ratio slalus disease Slalus survival for covanales
Meadows acUle Iymphocytic 327 = = = 0 = 0 + +(1983) leukemia
Manin various 2687 = = 0 0 + 0 0(1984) cancers
Boros Beute 130 0 0 0 0 0 + +(1985) nonlymphocytic
leukemla
Quoix small-celliung 215 = 0 0 = 0 +* 0(1986) cancer
Hunter various cancers 17773 0 0 0 0 0 0 0
(1987)
Goodwin various cancers 42724 0 0 0 0 0 0 0
(1988)
Michaelis childhood 210 0 0 0 0 0 0 + 0
(1988) osteosarcomn
Win~er anaplastie glioma 197 0 0 0 0 + + 0(198 )
~alainen multiple myeloma 1978 = = 0 0 0 0 + +(19 9)
Stiller acule Iymphoblaslic 4070 0 = 0 0 0 0 + +(1989) leukentia
Ward stomach cancer 1209 0 0 0 0 0 0 + 0
(1992)
Hjorth multiple myeloma 300 = 0 0 = 0 + +*(1992)
• •
Table 2. Summary of studies comparing RCT participants and unselected (ie. both eligible
and ineligible) non-participants.
Legend:
+ - (compared to non-participants) RCT participants were reported to he older, more
likely to be male, more likely to he white, of higher socioeconomic status, have more
extensive disease, have a higher performance status, or he more likely to survive;
- (compared to non-participants) RCT p~rticipants were reported to be younger, more
likely to he female, more likely to be non-white, of lower socioeconomic status, have
less extensive disease, have a lower performance status, or be less likely to
survive;
= - no difference between the two groups;
o - information not reported on in article;
* - for one subgroup only.
•Table 3.
Study Contrais Analytic method(s) Covariates
•
Adjusted
survivaI
Lennox eligible
(1979)
Meadows unselected
(1983)
Boras unselected
(1985)
Karjalainen unselected
(1989)
Stiller unselected
(1989)
Bertelson eligible
(1991)
Hjorth unselecled
(1992)
design
logistic
stratification regression
proportional
hazards age gender stage treatment other
treatrnentcentre
platelet coun~
LDH,perf.
status.
antibiotics,
preleukemia,
fever
period of
diagnosis
+
+
+
+
+
=
+*
•Table 3. Studies showing a crude survival advantage for trial participants that also
adjusted survival data for covariates: method(s) used and covariates controlled for.
•
Legend:
Controls indicate whether the study used eligible non-participants ("eligible") or
unselected non-participants ("unselected") as the control group. (Outcome data for studies
with eligible non-participants as controls are found in table 1; outcome data for studies
with unse1ected controls are found in table 2). Analytic methods include: design,
stratified analysis, logis tic regression model, and Cox proportional hazards model.
Covariates include: age, gender, stage or extent of disease ("stage"), treatment received
("treatment"), and other covariates. Adjusted survival: + - survival advantage for trial
participants; - survival advantage for trial non-participants; = - no difference between
the two groups. * - difference for only one subgroup.
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Discussion: Summary of findings and implications
for the ethical review of clinical research
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Fitting the results of chapters 2 and 3 into the historical-
ethica1 schema
In the first chapter of the thesis l presented both a
normative and a historical context for issues regarding the
selection of subjects for clinical research. How do the
results described in the second and third chapters of this
thesis fit into the picture we have presented? Overall, l
have attempted in this thesis to characterize the
population(s) of persons studied in clinical trials. As
such, this work addresses the issue of the applicability, or
generalizability, of the results of trials to clinical
practice. Rather than a historical or ethical (normative)
approach, though, the work in this thesis adopts an
empirical approach to the question. How many patients end up
treated on clinical trials? What barriers prevent patients
from entering trials and which is the greatest? Are persons
who are treated in clinical trials similar -- in terms of
demographics, prognosis and outcome -- to persons treated in
clinical practice? These are all, of course, empirical
questions.
The ordering of the empirical questions in this work
was based on logical considerations regarding the
generaliza9ility of the results of randomized controlled
trials. The questions were posed in order of priority such
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that an affirmative answer would terminate the need for
subsequent questions. The questions, the reasoning behind
them, and the results in brief are as follows:
• Is a large proportion of patients with a given disease
treated in clinical trials? If aIl persons with a given
disorder, or at least a very substantial proportion of them,
are treated in clinical trials, then, ipso facto the results
of those trials would be widely generalizable. We found that
the proportion of patients who end up on clinical trials is
not weIl characterized for most diseases. Data from Tate et
aI' and from Friedman et al2 on the enrollment of cancer
patients in clinical trials indicate that ·only a small
proportion of cancer patients (1.6 - 3.7%) is treated in
clinical trials. This is likely also the case for clinical
trials examining most common diseases. Since only a
relatively small proportion of patients are treated in
clinical trials, we cannot be assured that the subjects in
trials do not differ from the general patient population in
important ways. Thus, it may be that the results of trials
are not broadly applicable to clinical practice .
• Are subjects randomly selected from the patient
population for participation in randomized controlled
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trials? For common medical conditions, even if only a small
proportion of a patient population is treated in a given
clinical trial, we could be reasonably certain that the
results of that trial were broadly applicable if the
participants were randomly selected from the patient
population and if the number of participants was reasonably
large. It seems that the selection of subjects for
participation in randomized controlled trials is anything
but random. Gotay reviewed accrual to cancer clinical trials
and found that protocol, physician and patient factors
presented significant and differential barriers to patient
enrollment' .
Much of the second chapter is devoted to an attempt to
characterize the relative selective force that each of these
factors exerts. Determining this is important for two
reasons. First, protocol factors, that is, criteria for
clinical trial eligibility, select patients on the basis of
factors -- such as demographic and prognostic criteria --
that are of obvious clinical importance. Thus, evidence that
eligibility criteria are the most significant selective
force would immediately cause us to suspect that trial
participants differed from non-participants. Second, and
more importantly, an understanding of which of these factors
is the largest barrier to trial enrollment would direct
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attempts to remedy the situation. If eligibility criteria
are the largest barrier, then criteria could be more closely
scrutinized and, if possible, eliminated; if physician
factors are the most important, physicians could be targeted
for educational or incentive programs; if patient factors
proved to be the main factor, patients could be educated
about clinical trials or (more radically) consent modifying
procedures could be considered.
The literature reviewed in second chapter summarizes
the findings presented in twenty published reports
describing the enrollment experience of 148,561 potential
research subjects. Of subjects for whom a trial was
available for their type and stage of disease (and who
themselves were available for the trial), 32% were actually
enrolled in a randomized controlled trial. Eligibility
criteria were the largest barrier to trial enrollment for
these potential subjects: 53% were excluded by criteria for
trial eligibility. Physician factors and patient factors
each accounted for 7% of the subjects excluded (and 1% were
not enrolled for other reasons). These findings indicate
that there is good reason to believe that patients treated
in clinical trials may not be comparable in important ways
to the general patient population. Furthermore, whatever
differences exist between persons treated in clinical trials
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and those treated in clinical practice are likely the result
of criteria for trial eligibility.
• Are clinical trial participants comparable to non-
participants? The third chapter tackles the issue of the
comparability of patients treated in clinical trials with
those treated in clinical practice head on. Nine variables
of interest -- including demographic, prognostic and outcome
variables -- were defined a priori. In total, 19 empirical
studies were retrieved from the literature which compared
trial participants and non-participants with regard to at
least one of the variables of interest. Building on the
results of the second chapter which suggested that any
differences observed would likely be due to eligibility
criteria, the comparisons were divided into two groups:
comparisons of trial participants with eligible non-
participants; and, comparisons of trial participants with
both eligible and ineligible trial non-participants. If
criteria for trial eligibility are indeed the cause of any
differences then, we would expect to observe differences in
only the second group. The study presented in the third
chapter was designed to answer two questions: (1) Do
subjects who are treated on trial differ from study non-
participants with regard to any of the variables of
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interest; and, (2) Are these differences, if any, due to
criteria for trial eligibility?
The resu1ts presented in the third chapter show that
substantial differences do indeed exist between clinical
trial participants and non-participants. Subjects enrolled
in trials are significantly younger than trial non-
participants. Subjects enrolled in trials may also have
better performance status scores than non-participants,
although too few studies reported on this variable to allow
this to be concluded with confidence. These differences were
only apparent in comparisons of participants with unselected
non-participants and, thus, they were likely due to criteria
for trial eligibility. Subjects enrolled in clinical trials
also tended to survive longer than patients treated in
clinical practice. It could not be determined from the
results whether this represented a survival advantage
conferred by the (presumably) more fastidious treatments
offered in clinical trials or the selective effect exerted
by eligibility criteria or sorne other factor.
Thus, the results of this study underscore the
importance of the concern expressed in the last few years by
ethicists, politicians and patient activists regarding the
applicability of the results of clinical research to the
heterogeneous patient population at large. Our failure to
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find differences with regard to gender or race between trial
participants and non-participants is, however, surprising.
Confirmation of this finding will have to await further
study.
Nonetheless, the empirical literature which has been
used to bols ter claims of the "ubiquitous" exclusion of
women and racial/ethnie minorities from clinical research
bears re-examination. Very few empirical studies have
addressed the exclusion of racial/ethnie minorities from
research (Svensson's study' is the only one of which l am
aware) and the contention that minorities have been under
represented in clinical research remains unproven. There is
more empirical evidence to suggest that women have been
systematically excluded from certain categories of phase II
and III clinical trials, particularly cardiovascular
trials. 5 • 6 As l argue in chapter 3, though, the gender
discrepancy observed in cardiovascular trials may be
explained by age-based exclusion criteria.
Recall that (in our review of the history of ethical
concerns regarding the selection of subjects, Chapter one)
the predominant concern in the 1970s -- the equitable
distribution of burden -- was based on the belief that
research participation was an activity laden with risk. A
number of empirical studies (cited in chapter one)
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estab1ished that this premise was, for the most part, false.
So too/ l contend, the emphasis placed on the issue of the
exclusion of women and racial/ethnie minorities from
clinical research, as exemplified by the new NIH Guidelines,
is grounded in a false or exaggerated premise. The exclusion
of the elderly from clinical trials may be a more widespread
and, hence, more important problem.
Implication of these findings for the review of research by
Institutional Review Boards
The obligations of the Institutional Review Board in
the review of clinical research are detailed in the
Department of Health and Human Services Regulations (revised
1991).7 The portion of the regulations pertaining to the
selection of subjects was cited in extenso in the first
chapter and, in brief, it charges the IRB to ensure that the
"selection of subjects is equitable" (§46.111(a) (3)). The
Institutional Review Board Guidebook interprets this to mean
that the IRE must ensure that both the burdens and benefits
of the research are equitably distributed." Thus, with
regard to the former (burden), IRBs must ensure that
"vulnerable" populations (such as those incapable of giving
consent) are not unnecessarily or inappropriately included
in research. If circumstances so require, IREs may insist
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that a "vulnerable" group be excluded from a given study.
With regard to the distribution of benefit, investigators
and IRBs are cautioned not to "overprotect vulnerable
populations so that they are excluded in from participating
in research in which they wish to participate".8 Thus, IRBs
may question criteria for clinical trial eligibility that
seem to exclude groups of affected individuals who may
benefit from participation without justification. In the
absence of an acceptable justification, an IRB may make the
elimination of the eligibility criterion in question a
condition of the study's approval.
The "NIH Guidelines on the Inclusion of Women and
Minorities as Subjects in Clinical Research", described in
sorne detail in chapter one, require applicants for NIH
funding to ensure that women and racial/ethnie minorities
are adequately represented in clinical research proposaIs."
The Guidelines gives IRBs a role in ensuring that their
objectives are fulfilled. When reviewing applications for
NIH funding, IRBs must review procedures for subject
selection and ensure that the exclusion or inadeguate
representation of women or racial/ethnie minority groups is
carefully and adequately justified. Furthermore, IRBs have
an important educational role to play in the success of the
Guidelines. Educating investigators as to the importance of
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research with broad1y applicable results need not, of
course, only be directed at investigatars who are applying
for NIH funding. Sa tao, institutional guidelines and
procedures for enrolling and retaining women and
racial/ethnie minorities in research studies need not be
restricted to NIH funded research.
A strict interpretation of the new NIH Guidelines does,
however, limit the IRB's role in questioning eligibility
criteria that limit the generalizability of the study to
applications for NIH funding. But, according to the NIH
Guidelines, can IRBs only question criteria for trial
eligibility that explicitly deal with women or racial/ethnie
minorities? Since the stated purpose of the Guidelines is ta
ensure (in the case of phase III triais) "sufficient and
appropriate entry of gender and racial/ethnie subgroups"
i.e., adequate representation (rather than mere access), it
may be argued that IRBs can also direct their attention to
eligibility criteria that indirectly hinder the enrollment
of women or minorities to trials. 9 Thus, based on our
research findings, an IRB may question a criterion in a
cardiovascular disease trial that excludes, for example,
persons over the age of seventy years on the basis that it
will disproportionately exclude women from trial
participation. It will, of course, be the IRB's obligation
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to establish the connection between the criterion in
question and gender or minority enrollment.
But what of research that does not fall under the NIH
Guidelines? What is the place for a critical assessment by
the IRB of the generalizability of a study in the Department
of Health and Human Services Regulations? Let me highlight
one possible approach to this difficult problem with an
example.
Recall that in the discussion section of chapter three
we presented a hypothetical randomized controlled trial
which involved testing a new drug versus placebo in the
setting of post-myocardial infarction. 'O The endpoint of the
study was mortality and the sample size was calculated on
the basis of an expected 10% mortality in the control group,
7.5% mortality in the experimental group, power of 90%, and
probability of type l error of 1%. Given these assumptions,
the required sample size is (approximately) 4000 persons per
group or about 8000 in total. To bring out the issues at
play here, l would like to add the following "complications"
to this scenario:
• The investigator has non-NIH funding .
• The investigator, mindful of the political tenor of the
times, plans to enroll only women in the study. She outlines
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plans for actively accruing women to the study and projected
accrual goals that seem realistic.
• Strong evidence exists that men and women may respond
qui te differently to the proposed treatment regimen. (For
the purposes of the example, allow me to remain somewhat
vague about this). The strength of evidence is such that the
committee feels, after consulting with a number of expert
practitioners, that, were the issue of gender difference
addressed in the study, it would have to be addressed in the
primary analysis of the study .
• Finally, with regard to the study itself, let us assume
that aIl of the interventions in the study (monitoring,
blood tests, ECGs, cardiac catheterization at baseline) can
be considered as part of the optimal care of patient post-
myocardial infarction. AlI, that is, but two. The
investigator proposes to add a research intervention to a
randomly selected 5% subset of patients on both arms of the
study, namely, cardiac biopsy at the time of the first
coronary angiogram and another cardiac catheterization with
biopsy at six weeks post-MI. Although the added procedures
entails sorne risk -- including a small chance of death as a
result of the procedure, the investigator asserts that
important information regarding the effect of the study
agent on cardiac tissue may be gained by the procedure. As
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we11, she asserts, valuable information may be gained about
the relationship between histological changes and the
clinical course of patients post-MI. To reiterate, these
procedures are without therapeutic justification; their
purpose is to obtain more knowledge about cardiac disease in
general.
In the design of the trial, mindful of the fact that
men and women will likely respond differently to the
proposed treatment, the investigator has restricted the
study population to women. This will, assuming a fixed
sample size, increase the validity of the study; many more
subjects would be needed to prove the efficacy of the
treatment in men as weIl in women. What has been gained in
validity, though, has been at the cost of generalizability.
The results of this study will only apply to a subset of
persons with cardiovascular disease, namely, women. Freedman
and Shapiro have observed that this trade-off is inherent in
defining the eligible population of a clinical trial:
One major choice is settled, knowingly or
unknowingly, in setting eligibility criteria, that
of validity vs generalizability. When a controlled
trial imposes rigid criteria, the aim is to narrow
the population to two groups similar in as many
relevant respects as feasibly may be determined,
differing only on the allocation of treatment of
the two groups. Such a 'fastidious' trial is
intended to present the cleanest possible
scientific comparison. The choice though loses in
generalizability what it may have gained in
validity. The trial is intended to teach us
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something about the treatment of patients, who do
not have the luxury of checking a list of
eligibility criteria before choosing to become
ill. The clinical goal of a trial -- can be
sacrificed in 'fastidious' trials to an unyielding
commitment to scientific validity.ll
How does the restricted generalizability of the trial fit in
to the ethi r 11 analysis of the study?
The ethical assessment of the generalizability of a
study is a part of the assessment of its scientific value.
Regarding the evaluation of the value of a study, Freedman
has noted that
[ml ost important, a judgement of value must
include a view about the significance of the
hypothesis itself: for reason of its novelty,
clinical or other social implications, scientific
interest, or otherwise.
This would also be the occasion for broadly
considering to what degree the proposaI represents
a duplication of established results or instead
adds significantly to what the scientific
communi ty already knows. 12
The generalizability of a study defines its "clinical or
other social implications· and, thus, generalizability is a
subset of scientific value. The results of a narrowly
focussed clinical trial, aimed at only a subset of the
patient population, will likely only have "clinical ...
implications· for that ~estricted population subset.
Conversely, the results of a broad-based trial which
includes a representative sampling of the patient population
for a given Medical disorder, May have substantial clinical
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implications for the entire patient population. Thus, wide1y
genera1izab1e c1inical trials have more scientific value
that narrowly generalizable trials. In the Department of
Health and Human Services Regulations, this assessment of
the value of a study, and hence the assessment of its
generalizability, is incorporated into the overall risk-
benefit calculus. Namely, §46.111(a) (2) requires that IRBs
ensure that
[r]isks to subjects are reasonable in relation to
anticipated benefits, if any, to subjects, and the
importance of the knowledge that may reasonably be
expected to result. 7
Colleagues and l have argued elsewhere that the risks
of therapeutic elements of clinical research must be
analysed separately from the risks of interventions that
carry no therapeutic warrant. 13 We have referred to the
former as "therapeutic risk" and the latter as "dedicated
research risk". Therapeutic interventions, as their
associated risks, must satisfy the principle of clinical
equipoise. As we point out,
[f]or a nonvalidated intervention to be in
equipoise with a standard treatment arm, its
associated expectations of risk and benefit must
be roughly equivalent to those of treatments used
in clinical practice (or placebo if no treatment
is commonly accepted) .13
Thus, in this trial, the new therapy and the interventions
done with therapeutic intent (blood tests, ECG, the initial
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cardiac catheterization) must be in equipoise with standard
therapy. This, as we have said, may be presumed to be the
case.
Research interventions that present "dedicated research
risk" must be weighed separately from therapeutic
interventions. According to §46.111(a) (1), IRBs must ensure
that dedicated research risks are minimized
(I) by using procedures which are consistent with
sound research design and which do not
unnecessarily expose subjects to risk, and (ii)
whenever appropriate , by using procedures already
being performed on the subjects for diagnostic and
treatment purposes.'
The IRB must furthermore ensure that these risks are
reasonable in relation to "the know1edge that may reasonably
be expected to result". Thus, the analysis of dedicated
research risks does not involve a risk-benefit analysis, but
rather a "risk-knowledge" analysis.
The "knowledge that may reasonably be expected to
resu1t" from a study is in part a function of the
generalizability of a study. More broadly-generalizable
studies produce results which are more important; narrowly
defined, that is narrowly generalizable, studies produce
results that are less important.
In our example, then, the IRB must ensure that the
risks of the dedicated research interventions -- cardiac
biopsy and cardiac catheterization -- are minimized and are
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justifiable in relation to the importance of the knowledge
likely to be gained. The dedicated research interventions in
our example were intended to seem difficult to justify in
the context of a study that is less than very important.
(Let us at least assume this to be the case). Thus, the IRB
may weIl decide that, in the context of a study that is not
widely generalizable, such as one restricted to the study of
one gender, these risks are unacceptable. Given this
conclusion, two options are: (1) the interventions may
either be eliminated from the study or, (2) if the
investigator is unwilling to make this concession, the study
as a whole may be disallowed.
A third option exists. Implicit in what we have said is
that these dedicated research interventions may be allowable
in a study which is either more generalizable or more
important or both. Were the study to address the treatment
of both men and women post-MI, the increased
generalizability and importance of the study may be
sufficient to allow the IRB to approve the dedicated
research interventions. As we have said, though, this would
require a much larger sample size. According to the
discussion presented in chapter 3, to address the issue of
gender in the primary analysis (with the same power, etc.),
a total of 16000 subjects would be needed: 8000 men and 8000
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women, with approximately equal numbers of each group
assigned to the two treatment arms.
Note weIl though that in this case increasing the
sample size of the study is more or less incidental to
increasing the scientific value of the study. The ethical
acceptability of the revised study derives from the fact
that the study question has been changed: The initial study
asked (with respect to the dedicated research intervention),
"How do histological changes in the heart correlate with
survival of women post-myocardial infarction?" The revised
study asks a different question, namely, "How do these
changes correlate with the survival of men and women post-
myocardial infarction?" The latter study is acceptable not
because it is a larger study, but rather because it asks a
more important question.
with ·this example, l have attempted to demonstrate that
considerations of the generalizability of a study can, and
indeed ought, to be incorporated into the ethical analysis
of research under current DHHS Regulations. Ethical
considerations regarding the selection of subjects, of
course, involve considerations regarding the equitable
distribution of the burdens and benefits of a study. This
example has attempted to highlight the fact that
considerations regarding the generalizability of a study are
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a subset of va1ue-re1ated considerations. As such,
generalizability is weighed against dedicated research risks
in the lRB's analysis of the risks of research. It follows
that more dedicated research risk is allowab1e for studies
that are widely generalizable -- that is, addressing a
question that is of more scientific value -- than those that
have narrowly defined study populations.
Although we have begun to characterize the relationship
between generalizability and ethically acceptable risk in
clinical research, questions remain as to the relationship
between scientific value (broadly construed) and research
risk. How ought the potential social impact -- apart from
considerations of generalizability per se -- of a clinical
trial be incorporated into its ethical analysis? ls the
level of allowable dedicated research risk greater for
trials involving diseases that affect more people in society
than other diseases (say trials involving lung cancer versus
those involving cancer of the cervix, or trials in HlV/AIDS
versus gene therapy protocols for adenosine deaminase
deficiency)? If this is the case, then persons who suffer
from a common disease could be exposed to more risk without
the prospect of therapeutic benefit in a clinical trial than
those who suffer from rare diseases. Clearly, work is needed
to resolve this issue.
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Original contributions in this thesis
The Guide1ines for Thesis Preparation allow persons
submitting Masters thesis the option of indicating which, if
any, portions of the thesis represent original
contributions. The following portions of this thesis are
original contributions:
-the historical overview of evolving ethical issues in the
selection of subjects for c1inical research (chapter one);
- the "meta-analytic" review of the literature presented in
the second chapter which derived quantitative estimates of
the proportion of patients excluded by protocol, physician
and patient factors;
- the "meta-ana1ytic" review of the literature presented in
the third chapter which identified differences between trial
participants and non-participants and which suggested that
these differences were large1y due to criteria for trial
eligibility;
- the solution to the purported dilemma regarding proof of
effect in subgroups versus the ethical requirement not to
deny trial participants "proven" therapy when an effect has
been dernonstrated in the aggregate (discussion, chapter
three);
and, finally,
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-the ana1ysis of the incorporation of generalizability into
current understanding of the ethical analysis of research
required by DHHS Regulations (chapter four) .
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